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ABSTRACT: The 4EGI-1 is the prototypic inhibitor of
eIF4E/eIF4G interaction, a potent inhibitor of translation
initiation in vitro and in vivo and an eﬃcacious anticancer
agent in animal models of human cancers. We report on the
design, synthesis, and in vitro characterization of a series of
rigidiﬁed mimetic of this prototypic inhibitor in which the
phenyl in the 2-(4-(3,4-dichlorophenyl)thiazol-2-yl) moiety
was bridged into a tricyclic system. The bridge consisted one
of the following: ethylene, methylene oxide, methylenesulﬁde,
methylenesulfoxide, and methylenesulfone. Numerous ana-
logues in this series were found to be markedly more potent
than the parent prototypic inhibitor in the inhibition of eIF4E/
eIF4G interaction, thus preventing the eIF4F complex formation, a rate limiting step in the translation initiation cascade in
eukaryotes, and in inhibition of human cancer cell proliferation.
■ INTRODUCTION
Translation initiation in eukaryotic cells is a highly regulated
process and plays an important role in cell proliferation,
diﬀerentiation, survival, and maintenance of homeostasis.1
Disruption and/or perturbation of cap-dependent translation
is associated with many pathophysiological processes such as
Wolcott−Rallison syndrome, fragile X syndrome,2 neuro-
degenerative disorders such as Alzheimer’s disease, and
proliferative disorders such as malignant transformation.3,4
Translation initiation commences with the binding of the
eukaryotic initiation factor 4E (eIF4E) to the mRNA 5′-end-
cap (m7GpppN, where N is any nucleotide and m is a methyl
group) structure, which is present in all mRNAs. Protein−
protein interaction between eIF4E and eIF4G, the scaﬀolding
protein, enables the recruitment of eIF4A, a DEAD-box RNA
helicase, and formation of the eIF4F complex that unwinds the
secondary structure of mRNAs and allows the docking and
assembly of the 43S pre-initiation complex.5 The 40S ribosome
complex then traverses the 5′ untranslated region (UTR) until
it recognizes the initiation codon AUG, followed by the 60S
large ribosomal subunit binding to form the 80S initiation
complex, which is competent to enter the elongation cycle.6,7
Under normal cellular conditions, eIF4F complex is limited
as eIF4E is secluded from eIF4G by binding to hypophos-
phorylated eIF4E binding proteins (4E-BP). Stimulation of the
phosphatidylinositol 3-kinase/AKT/mTOR pathway leads to
hierarchical 4E-BP phosphorylation, dislodging hyperphos-
phorylated 4E-BP from eIF4E and enabling assembly of
eIF4F complex. Because both the 4E-BPs and eIF4G share
the same binding motif on eIF4E,8−10 the former can function
as an endogenous inhibitor of cap-dependent translation
initiation. As such, ectopic overexpression of 4E-BP can inhibit
cap-dependent protein synthesis, inhibit tumor growth, and
revert the malignant phenotype of eIF4E-overexpressing cancer
cells.
eIF4F complex assembly is rate limiting for translation
initiation and is predominantly dependent on the availability of
eIF4E. Although eIF4F complex formation increases the
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translation of all cap-dependent mRNAs and thereby increases
global protein synthesis rate, mRNAs vary widely in their
inherent “translatability”, that is, primarily dictated by the
length and structure of their 5′-UTRs. mRNAs with long and
structurally complex 5′-UTRs (i.e., “weak” mRNAs) are most
sensitive to restrictive abundance of eIF4E and therefore to the
limited availability of the eIF4F complex. These “weak”
mRNAs, which encode proteins that play important roles in
cell growth, proliferation, and apoptosis,11,12 are poorly
translated when eIF4F complex is scarce, due to ineﬃcient
unwinding of “weak” mRNA and subsequently preventing
ribosome loading. In contrast, most mRNAs that are
characterized by relatively short, unstructured 5′UTRs, the
so-called “strong” mRNAs, express housekeeping proteins such
as β-actin, continue to be eﬃciently scanned to achieve robust
initiation codon recognition, eﬀective ribosome loading, and
eﬃcient translation even when eIF4F complex levels are
limiting.13
Dysregulated eIF4E-dependent translational control is
implicated in the pathobiology of human disorders including
autism,14 fragile X syndrome,15 tuberous sclerosis,16 and some
cancers.17 eIF4E function is particularly critical for the
expression of a wide array of proteins that contribute to all
aspects of malignancy, including growth factors such as c-myc
and cyclin D1, angiogenesis factors such as VEGF and FGF-2,
and antiapoptotic proteins such as survivin and Bcl-2.13
Inhibition of either eIF4E expression by antisense RNA or
the eIF4E/eIF4G interaction by overexpression of 4E-BPs
reverses the malignant phenotype in vitro and in vivo.18 Hence,
disrupting the formation of eIF4F complex will retard
translation initiation in general and in particular translation
initiation of “weak” mRNAs that encode a wide array of
proteins involved in pathophysiological processes, including
pro-oncogenes, growth factors, cell cycle regulators, and
transcription factors, will yield powerful molecular probes and
may lead to novel drug candidates.19−21
We have previously reported the discovery of (2-(2-(4-(3,4-
dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)-
propanoic acid) (1), the eIF4E/eIF4G inhibitor-1 (4EGI-1),
which inhibits protein−protein interaction.22 The high
throughput screening (HTS) campaign of small molecule
libraries employed a cell free ﬂuorescence polarization assay
(FP). In vitro, 1 inhibits expression of regulatory proteins such
as cyclins D1 and E, C-myc, and Bcl-2 without aﬀecting the
expression of housekeeping proteins such as actin and α-tubulin
and enhances the dissociation of eIF4G from eIF4E. Moreover,
we reported signiﬁcantly lower IC50 for the inhibition of
proliferation of transformed malignant Ph+, which is trans-
formed by the bcr-abl, cells than that for nonmalignant
nontransformed Ph− cells by 1.22 Similarly, Tamburini et al.
reported that 1 dramatically reduces the clonogenic growth of
AML progenitors with a moderate impairment of normal
CD34+ hematopoietic progenitor cologenicity.23 Together,
these studies support the proposition that inhibition of cap-
dependent translation initiation will aﬀect predominantly cells
whose growth is fast or unregulated rather than normal cells.8
In vivo, it eﬀectively inhibits xenograft tumor growth in a
mouse model of human cancer.24 Moreover, 1 proved to be an
important molecular probe in understanding the role of eIF4F
in memory formation and consolidation,25 autism spectrum
disorders,26 and viral infection.27
Titration of GB1-eIF4E, a fusion protein tagged with a
solubility enhancing domain, with 1 and measuring the 15N-
HSQC spectrum suggests that it is binding to residues present
Scheme 1. Strategy for the Rigidiﬁcation of 1
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on the eIF4G-binding surface of eIF4E.22 In the absence of high
resolution structure of the complex of 1 with eIF4E we carried
out extensive structure−activity relationship studies to identify
the essential pharmacophore and understand the structural
latitude presented by this prototypical inhibitor of eIF4E/
eIF4G interaction.28,29 Structural rigidiﬁcation that introduces
conformational constraint around rotatable bonds was practiced
advantageously in many systems and was reported to contribute
to higher speciﬁcity and potency, greater metabolic stability,
and improved bioavailability.30−36
In light of the importance of the phenyl substitution on
position 4 of the thiazolidine ring, we sought to delineate the
spatial relationship between these two aromatic moieties by
restricting the rotation around the bond connecting the two
rings. Ring closure between the 1- or 6-position of the 3,4-
dichlorophenyl ring (C) and the 5-position of the thiazolidine
ring (B) in 1 will generate nearly coplanar, condensed, and
rigid tricyclic systems that are formally formed by rotamers
representing dihedral angles of 0° and 180° around the bond
connecting the 4-thiazolyl and the phenyl ring (Scheme 1,
structures type P1 and type P2). Speciﬁcally, the resultant rigid
tricyclic scaﬀolds generated by bridging position 5 of the
thiazolidine with the ortho position of the phenyl ring
(substituting position 4 of the same thiazolidine ring) via one
of the following linkers, ethylene, methylene oxide, methyl-
enesulﬁde, methylenesulfoxide, and methylenesulfone, will fuse
the thiazolidine ring to 3,4-dihydrotetralin, chromene,
thiachromene, oxothiachromene, and thiodioxochromene,
Scheme 2. Synthetic Strategy of Partially Rigidiﬁed 1 Mimetic
Scheme 3. Synthesis of 4,5-Dihydronaphtho[1,2-d]thiazolyl-Containing 1 Mimetica
a(i) Succinic anhydride, AlCl3, 65 °C, 80%; (ii) succinic anhydride, n-BuLi, −78 C, 30%; (iii) Zn(Hg), concd HCl, toluene, reﬂux, 36 h, 30−60%;
(iv) polyphosphoric acid, 130 °C, 12 h, 30%; (v) Br2, ether, 30 min, 88−90%; (vi) thiosemicarbazide, dioxane, 48 h, 40−50%; (vii) 2-(o-
nitrophenyl)pyruvic acid, 5% AcOH in EtOH (1:2, v/v), reﬂux, 1 h, 38−45%.
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respectively. Evidently, these fused tricyclic scaﬀolds are found
in many biological active compounds. For example: 4,5-
dihydronaphtho[1,2-d]thiazole scaﬀold is found in a ligand
that has signiﬁcant 5-HT3 receptor aﬃnity37 and in ligands that
act as allosteric enhancers of A1 adenosine receptors;38 4H-
chromeno[4,3-d]thiazole scaﬀold is present in some anti-
bacterial agents;39 4H-thiochromeno[4,3-d]thiazole scaﬀold has
been reported to constitute agents with antimicrobial, analgesic,
anti-inﬂammatory, and anesthetic activities,40,41 and 4H-
sulfoxo- and 4H-sulfonochromeno[4,3-d]thiazole scaﬀolds
constitute some antifungal agents.42
With the intention to characterize the impact of partial
molecular rigidiﬁcation, we connected rings B and C forming
either the 3,4-dihydrotetralin or chromene ring systems. We
have focused our study on the previously reported prototypic 1
and kept the o-NO2-substitution on ring A and the dichloro-
substitution on ring C. In addition, we substituted ring C with
the more polar dimethoxy-substitutions. Our study reported
herein explored the role of conformational rigidiﬁcation of the
4-[3′,4′-dichlorophenyl]thiazolyl part of 1 on its potency to
inhibit eIF4E/eIF4G interaction employing a ﬂuorescence
polarization assay and proliferation of human cancer cells.
■ RESULTS AND DISCUSSION
Chemistry. Conceptually, there are two possible modes for
connecting rings B and C of 1 by forming a new six-membered
ring that is part of the fused tricyclic system. In the ﬁrst mode
(P1), position C5 of the 2-thiazolyl (ring B) and the position
C2′ of 3′,4′-dichlorphenyl (ring C) are connected to form the
new six-membered ring (Scheme 1, system I). In the second
mode (P2), the same position of the 2-thiazolyl (ring B) is
connected to C6′ of 3′,4′-dichlorphenyl (ring C), again forming
another variant of a fused tricyclic system (Scheme 1, system
II). In addition, the availability of (E)- and (Z)-conﬁgurations
around the carbimino bond of the hydrazono function enables
formation of two geometrical isomers for each of the two
cyclization modes described above. While the mode of
cyclization is dictated by the choice of starting material,
isomers (E) and (Z) are generated simultaneously as a mixture
that requires chromatographic separation. The purity of the
ﬁnal rigidiﬁed 1 mimetic was established by analytical RP-
HPLC and exceeded 95%, and their structural integrity and
identity was established by 1H- and 13C NMR and HR-MS.
Our stepwise synthetic strategy followed the general pathway
used in the synthesis of (E/Z)-1 (Scheme 2).43 Accordingly, α-
bromination of the bicyclic ketone 2 generated the correspond-
ing phenacyl bromide 3. Reaction of the bromide 3 with the
thiosemicarbazide led to the formation of the 2-hydrazinyl-
thiazole 4 that was then condensed with the o-nitro-
phenylpyruvic acid to generate the partially rigidiﬁed (E/Z)-1
mimetic 5 (Scheme 2).
Synthesis of the 4,5-dihydronaphtho[1,2-d]thiazolyl-contain-
ing 1 mimetic 13a and 13b is outlined in Scheme 3. Friedel−
Crafts acylation of o-dichlorobenzene, 6, with succinic
anhydride in the presence of AlCl3 or n-BuLi
44 led to the
formation of the respective isomers 4-(3,4-dichlorophenyl)-
and 4-(2,3-dichlorophenyl)-4-oxobutanoic acid (7a and 7b,
respectively). Clemmensen reduction of the ketones45,46 was
followed by intramolecular polyphosphoric acid-mediated
acylation,47 generating the corresponding α-tetralone deriva-
tives 9a45 and 9b46 that were then α-brominated to the
corresponding 2-bromo-6,7-dichloro-3,4-dihydronaphthalen-
1(2H)-one, 10a,46,48 and 2-bromo-5,6-dichloro-3,4-dihydro-
naphthalen-1(2H)-one, 10b. Hantzsch-type reaction49 between
thiosemicabazide and these α-bromoketones generated pre-
dominantly the corresponding hydrazines 11a and 11b in
Scheme 4. Synthesis of Chromene Derived 1 Mimetica
a(i) β-Propiolactone, NaH, DMF, 100 °C, 42%; (ii) β-propiolactone, NaOH, H2O, 100 °C, 50%; (iii) HFliq, −78 °C, 12 h, 76%; (iv) Eaton’s
Reagent, 70 °C, 75%; (v) pyridinium bromide perbromide, CHCl3−EtOH, 50 °C, 74−76%; (vi) thiosemicarbazide, dioxane, 40−50%; (vii) 2-(o-
nitrophenyl)pyruvic acid, 5% AcOH−ethanol (1:2, v/v), reﬂux, 1 h, 35−40%.
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moderate yields side-by-side with lesser amounts of the side-
product amines 12a and 12b. Finally, condensation between
4,5-dihydronaphtho[1,2-d]thiazol-2-yl)hydrazines, 11a and
11b, with 2-(o-nitrophenyl)pyruvic acid in the presence of
5% acetic acid aﬀorded the isomeric mixture of the desired
rigidiﬁed 1 mimetic, (E/Z)-13a (type P1) and (E/Z)-13b (type
P2) in 35−40% yield. The individual (E)- and (Z)-isomers
were separated by reverse phase column chromatography. In a
separate reaction, when a mixture of 11a and 12a treated with
2-(o-nitrophenyl)pyruvic acid under similar reaction conditions
only the formation (E/Z)-13a was observed with the unreacted
diazine 12a, presumably due to its weak nucleophilicity relative
to 11a. And also considering the tedious chromatographic
process required for the isolation of the hydrazine (11a) and
the thiadiazine (12a), it was decided to use the crude amine
mixtures in the syntheses of other analogical derivatives of 1
(compounds (E/Z)-23a−b, (E/Z)-29a−b, (E/Z)-32a−b, (E/
Z)-35a−b, and (E/Z)-46a−c, Schemes 4−7). The respective
yields of the hydrazines were based on the LCMS analyses of
the mixtures.
Synthesis of rigidiﬁed oxymethylene-bridged 1 mimetic (E/
Z)-23a (type P1) and (E/Z)-23b (type P2) started with O-
alkylation of 2,3-dichloro- and 3,4-dichlorophenol, respectively,
with β-propiolacone in the presence of sodium hydroxide or
Scheme 5. Synthesis of Thio-chromene Derived 1 Mimetica
a(i) 3-Bromopropionic acid, NaOH, 100 °C, 88−94%; (ii) concd H2SO4, −10 °C−RT, 90%; (iii) Br2, 60−69%; (iv) thiosemicarbazide, dioxane,
40−50%; (vi) 2-(o-nitrophenyl)pyruvic acid, 5% AcOH−ethanol (1:2, v/v), reﬂux, 1 h, 35−40%.
Scheme 6. Synthesis of Methylene Sulfoxide and Methylene Sulfone Derived 1 Mimetica
a(i) m-Chloroperbenzoic acid (1 equiv), CHCl3, RT, 70−76%; (ii) m-chloroperbenzoic acid (4 equiv), CHCl3, reﬂux, 72−83%; (iii)
thiosemicarbazide, dioxane, 40−50%; (iv) 2-(o-nitrophenyl)pyruvic acid, acetic acid, 2 h, RT, 40−42%; (v) 2-(o-nitrophenyl)pyruvic acid, acetic acid,
30 min, RT, 35−45%.
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sodium hydride. This was followed by acid catalyzed cyclization
of the 3-phenoxypropionic acids 15 and 18 into the
corresponding chroman-4-one derivatives 16, 19, and 20.50
While the cyclization of 3-(2,3-dichlorophenoxy)propanoic acid
(15) in the presence of either HFliq or Eaton’s reagent
51
aﬀorded 7,8-dichlorochroman-4-one (16) in good yield,
cyclization of 3-(3,4-dichlorophenoxy)propanoic acid (18) in
the presence of HFliq aﬀorded 7,8-dichlorochroman-4-one (19)
but in the presence of Eaton’s reagent it yielded 5,6-
dichlorochroman-4-one (20). Because of excessive steric
hindrance considerations, we shelved ketone 20 and carried
α-bromination of 16 and 19 successfully by employing
pyridinium bromide perbromide (PBPB).52 In contrast,
attempt to use Br2 under conditions similar to those used for
the preparation of 10a and 10b generated multiple products
and mixtures diﬃcult to resolve. Conversion of the α-bromo
ketones 21a and 21b followed to the hydrazines 22a and 22b
and the subsequent condensation with 2-(o-nitrophenyl)-
pyruvic acid followed the same procedures as described above
for the 4,5-dihydronaphtho[1,2-d]thiazolyl-containing 1 mim-
etic 13a and 13b and generated the anticipated oxymethylene-
bridged 1 mimetic (E/Z)-23a and (E/Z)-23b (Scheme 4).
As a logical extension of oxymethylene to thiomethylene
rigidiﬁed analogues of 1, the synthesis of a set of rigidiﬁed
mimetic of 1, 29a, and 29b was performed. The synthetic
protocol started from the S-alkylation of 2,3- and 3,4-
dichlorothiophenol with 3-bromopropionic acid in the presence
of sodium hydroxide at elevated temperature, yielding
respective thioaryl propionic acids, 25a and 25b, which on
H2SO4 cyclization aﬀorded 4-thiochroman-1-ones, 26a and
26b, in excellent yield.53 The 2-bromo-4-thiochroman-4-ones,54
27a and 27b, obtained from the thiachromanones 25a and 25b,
respectively, gave thiomethylene rigidiﬁed mimetic of 1, (E/Z)-
29a and (E/Z)-29b in 35−40% yields (Scheme 5) by following
the general synthetic steps described in Scheme 2.
With a view to functionalize the thiochromene derived
mimetic on the sulfur atom, α-bromo thiochromenes, 27a and
27b, were subjected to oxidation at diﬀerent conditions55 to
aﬀord 33a and 33b, which on treatment with thiosemicarbazide
followed by 2-(o-nitrophenyl)pyruvic acid gave the methylene
sulfoxide and methylene sulfone bridged 1 mimetic (E/Z)-32a,
(E/Z)-32b, (E/Z)-35a, and (E/Z)-35b, respectively (Scheme
6).
To examine the eﬀect of a dimethoxy substituent on the ring
A replacing a dichloro substituent, we synthesized three
dimethoxy substituted rigidiﬁed analogues of 1 starting from
the respective tetralone and chromanones. Thus, 6,7-
dimethoxy-4-chromanone (43a)56−58 aﬀorded (E/Z)-46a,
while 7,8-dimethoxy-4-chromanone (43b)59,60 and 6,7-dime-
thoxy tetralone (43c) obtained from 4-oxo-4-(3,4-
dimethoxyphenyl)butanoic acid (39)61 yielded (E/Z)-46b
and (E/Z)-46c, respectively, in analogy to Scheme 2 (Scheme
7).
Biology. Our previously described ﬂuorescence polarization
(FP) assay was used to measure the binding eﬃciency of new 1
mimetic to eIF4E by competing with a ﬂuorogenic eIF4G
derived peptide containing the conserved eIF4E-binding motif
(KRYDREFLLGF).22 Displacement of the Nα-ﬂuorescein
tagged eIF4G-drived peptide by a competing ligand causes a
measurable decrease in FP. The nontagged version of the same
eIF4G-derived peptide and DMSO were used as positive and
negative controls, respectively. The binding aﬃnity of the new
rigidiﬁed mimetic of 1 in which the 3,4-dichlorphenylthiazol-2-
yl system was replaced with either 4,5-dihydronaphthol[1,2-
d]thiazol-3-yl or 4H-chromeno[4,3-d]thiazol-3-yl moieties or
4H-thiochromeno[4,3-d]thiazol-3-yl or 4H-sulfoxo- and
Scheme 7. Synthesis of Dimethoxy Derivatives of Tetralin and Chromene Based 1 Mimetica
a(i) 3-Chloro propanoyl chloride, BF3·etherate, 60 °C, 3 h; (ii) K2CO3, RT, 20 h; (iii) succinic anhydride, AlCl3, nitrobenzene; (iv) Zn−Hg, concd
HCl, reﬂux, 40%; (v) P2O5, benzene, reﬂux, 4 h, 57−79%; (vi) oxetan-2-one, NaH, DMF (vii) P2O5, benzene, 90 °C, 6 h, 57%; (viii) pyridinium
bromide perbromide, CHCl3−EtOH, 50 °C, 30 min, 48−75%; (ix) thiosemicarbazide, dioxane; (x) 2-(o-nitrophenyl)pyruvic acid, 5% AcOH−
ethanol (1:2, v/v), 35−41%.
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sulfonochromeno[4,3-d]thiazol-3-yl moieties was tested in the
FP assay and were compared to that of (Z)-isomer of parent 1.
The results were presented as a ratio between the IC50 of (Z)-1;
the concentration of (Z)-1 needed to displace 50% of the
ﬂuorescent-tagged peptide, and the IC50 of the new 1 analogue,
and the concentration of the new analogue needed to displace
50% of the ﬂuorescent-tagged peptide when measured in the
same 384-well plate (Figure 1).
The simplest of the rigidiﬁed 1 mimetic, (E/Z)-13a,
containing an ethylene bridge between C-6′-(2′,3′-dichlor-
ophenyl) ring (C) and C-5 of thiazolyl ring (B), and (E/Z)-
13b, containing an ethylene bridge between C-2′-(4′,5′-
dichlorophenyl) ring (C) and C-5 of thiazolyl ring (B), display
a 1.5- to 2-fold increase in binding aﬃnity as compared to
parent (Z)-1 (entries 2−5, Table 1). Linking thiazolyl ring B
with the phenyl ring C via an oxymethylene (entries 6−9, Table
1) contribute to further increase in binding aﬃnity, reaching in
(Z)-23a a 3-fold increase (IC50 = 15.5 μM) relative to the
parent (Z)-1. However, rigidiﬁcation via bridges containing
thiomethylene (entries 10−13, Table 1), methylenesulfoxide
(entries 14−17, Table 1), or methylenesulfone (entries 18−21,
Table 1) reverse the trend and do not contribute to binding
aﬃnity enhancement relative to the nonrigidiﬁed parent 1.
Interestingly, the most potent binders to eIF4E in this series are
1 mimics containing the dihydronaphtho- and the chromeno-
ring systems carrying dimethoxy substituents (IC50 = 10.5 μM
for both (E)-46c and (E)-46a, respectively). A plausible
explanation for the decrease in binding aﬃnity of the polar
methylenesulfoxide- and methylenesulfone-containing 1 mim-
etic relative to the less polar thiomethylene- and oxymethylene-
Figure 1. Dose Dependent Inhibition of eIF4E/eIF4G interaction by
rigidiﬁed 1 mimetic.
Table 1. Binding of the 1 Rigidiﬁed Mimetic to eIF4E as Measured by Fluorescence Polarization Assay (FP) and Their Potency
to Inhibit Cancer Cells Proliferation As Measured by Sulforhodamine B (SRB) Assay
SRB assay IC50 (μM)
entry compd X R1 R2 R3 FP assay IC50 (μM) CRL-2813 CRL-2351
1 (Z)-1 Cl Cl H 43.5 ± 1.52 15.3 ± 2.5 11.6 ± 0.2
2 (E)-13a CH2 H Cl Cl 21.5 ± 0.70 3.8 ± 0.3 4.1 ± 0.7
3 (Z)-13a CH2 H Cl Cl 34 ± 4.24 12.0 ± 0.6 >20 (NA)
a
4 (E)-13b CH2 Cl Cl H 32 ± 1.41 3.6 ± 0.3 4.4 ± 0.6
5 (Z)-13b CH2 Cl Cl H 43.5 ± 2.12 10.6 ± 1.4 11.2 ± 0.6
6 (E)-23a O Cl Cl H 25 ± 1.41 5.8 ± 0.0 16.6 ± 4.2
7 (Z)-23a O Cl Cl H 15.5 ± 0.70 12.3 ± 0.4 >20 (NA)
8 (E)-23b O H Cl Cl 18.5 ± 0.70 3.1 ± 0.1 5.2 ± 0.6
9 (Z)-23b O H Cl Cl 27 ± 1.41 8.7 ± 4.1 15.4 ± 2.8
10 (E)-29a S H Cl Cl 15.5 ± 0.70 5.1 ± 0.1 17.6 ± 2.8
11 (Z)-29a S H Cl Cl 14 ± 0.0 10.5 ± 0.1 17.7 ± 2.7
12 (E)-29b S Cl Cl H 28 ± 1.41 4.5 ± 0.1 9.1 ± 1.3
13 (Z)-29b S Cl Cl H 11.5 ± 0.70 7.0 ± 2.2 16.7 ± 0.1
14 (E)-32a SO H Cl Cl 30.5 ± 2.12 7.5 ± 0.7 >20 (NA)
15 (Z)-32a SO H Cl Cl 30 ± 1.41 4.1 ± 0.1 10.3 ± 0.4
16 (E)-32b SO Cl Cl H 48.5 ± 6.36 11.2 ± 1.7 >20 (NA)
17 (Z)-32b SO Cl Cl H 32.5 ± 2.12 11.4 ± 0.3 19.8 ± 0.3
18 (E)-35a SO2 H Cl Cl 40.5 ± 6.36 >20 (NA) >20 (NA)
19 (Z)-35a SO2 H Cl Cl 39 ± 5.65 >20 (NA) >20 (NA)
20 (E)-35b SO2 Cl Cl H 49 ± 2.82 >20 (NA) >20 (NA)
21 (Z)-35b SO2 Cl Cl H 49 ± 2.82 >20 (NA) >20 (NA)
22 (E)-46c CH2 H OMe OMe 10.5 ± 0.70 12.1 ± 0.7 >20 (NA)
23 (Z)-46c CH2 H OMe OMe 45 ± 2.82 >20 (NA) >20 (NA)
24 (E)-46b O OMe OMe H 16.5 ± 3.53 >20 (NA) >20 (NA)
25 (Z)-46b O OMe OMe H 55.5 ± 4.94 >20 (NA) >20 (NA)
26 (E)-46a O H OMe OMe 10.5 ± 0.70 >20 (NA) >20 (NA)
27 (Z)-46a O H OMe OMe 51.5 ± 4.94 >20 (NA) >20 (NA)
aNA: not active.
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containing analogues is the marked decrease in the calculated
partition coeﬃcient (CLogP) associated with the increased
polarity. Comparison of CLogPs of (Z)-isomers of 13a (5.21),
23a (4.65), 29a (4.96), 32a (3.15), and 35a (2.88) that are
constrained by the respective ethylene-, oxymethylene-, thio-
methylene-, methylenesolfoxide-, and methylenesulfone-bridges
supports the above-mentioned proposition.
Evidently, regardless of the substitution on ring C (dichloro
or dimethoxy), we do not observe a signiﬁcant diﬀerence in
binding aﬃnity trends between type P1 (a series) and type P2
(b series) for the rigidiﬁed 1 mimetic (e.g., cf. IC50 in the FP
assay of (E)-13a and (Z)-13a with (E)-13b and (Z)-13b, 21.5
and 34 with 32 and 43.5 μM, respectively, or (E)-46a and (Z)-
46a with (E)-46b and (Z)-46b, 10.5, 30, and 51.5 with 16.5 and
55.5 μM, respectively).
The inhibition of cell proliferation data obtained in the SRB
(sulforhodamine B) cell proliferation assay with human cancer
cell lines CRL-2351 breast and CRL-2813 melanoma indicated
that the rigidiﬁed 1-derived mimetic inhibited cell proliferation
with IC50 values around 1−20 μM. With few exceptions that
might relate to solubility and/or cell penetration issues, almost
all compounds displaying higher aﬃnity to eIF4E than (Z)-1 in
the FP assay were also more potent inhibitors in the SRB cell
proliferation assay, suggesting that the compounds inhibit cell
proliferation through inhibition of translation initiation. In
comparison with the parent nonconstrained 1 that inhibits
equally the breast cancer and melanoma cells, the rigidiﬁed 1
mimetic compounds were, in general, more potent in inhibiting
proliferation of CRL-2813 melanoma cells vs the CRL-2351
breast cancer cells. While (Z)-13a, (Z)-23a, (E)-32a, and (E)-
32b (IC50= 12.0, 12.3, 7.5, and 11.2 μM, respectively) were
slightly more potent than (Z)-1 (IC50= 15.3 μM) in inhibiting
proliferation of the melanoma cells, they did not inhibit the
proliferation of breast cancer cells up to 20 μM. Interestingly,
the more polar rigidiﬁed 1 mimetic compounds, those that are
composed of 4H-[1]benzothiopyrano[4,3-d]thiazole, 5,5-diox-
ide (35a and 35b, CLogP = 2.88), and dimethoxy-substituted
dihydronaphtho[1,2-d]thiazole (Z)-46c, CLogP = 3.63) and
4H-chromeno[4,3-d]thiazole (46a and 46b, CLogP = 2.98), in
spite of having inhibitory binding aﬃnity comparable to that of
(Z)-1 (CLogP = 4.76) were devoid of cell proliferation
inhibitory activity up to concentrations of 20 μM.
Evidently, we think of the cancer cell proliferation inhibitory
activities as reporting of global activity that combine on- and
oﬀ-target eﬀects. The high sensitivity of the adherent human
melanoma CRL-2813 relative to the human breast cancer CRL-
2351 to inhibition of proliferation by the rigidiﬁed 1 mimetic
compounds may be attributed to the presence of a BRAF
mutation that makes them signiﬁcantly more dependent on
highly eﬃcient cap-dependent translation initiation.62
Disruption of eIF4E/eIF4G Interaction. We chose (E)-
29a, a rigidiﬁed 1 mimetic that showed enhanced potency in
the FP-assay and the SRB-cell proliferation assay, and (E)-35b,
another 1 mimetic with very low activity in both assays, and
tested their ability to disrupt the eIF4E/eIF4G complex
formation in CRL-2813 melanoma cells (Figure 2). The state
of association of eIF4E with eIF4G and 4E-BP1 was
determined by pull-down experiment on m7GDP agarose
resin. This demonstrated that full-length eIF4G is displaced
from eIF4E by (E)-29a that was not the case with the FP-less
active derivative (E)-35b, in which no eﬀect was observed. The
disruption of the eIF4E/eIF4G, however, increased the 4E-BP1
binding to eIF4E, which is consistent with our previous ﬁnding
that 1 inhibits eIF4E/eIF4G interaction independently of 4E-
BP1 binding to eIF4E.24 We speculated that this increase in the
amount of eIF4E/4E-BP1 complex is likely due to the
dissociation of eIF4G that exposes of a larger 4E-BP1 binding
footprint that is present on eIF4E and is partially obscured by
the bound eIF4G.22
■ CONCLUSIONS
In an eﬀort to optimize 1, the hit compound that was found to
inhibit eIF4E/eIF4G protein−protein interaction and trans-
lation initiation both in vitro and in vivo, as a molecular probe
and potential drug candidate, we focused on developing a
rigidiﬁed 1 mimetic. Rigidiﬁcation of the 2-(4-(3,4-
dichlorophenyl)thiazol-2-yl) moiety by introduction of a
ethylene, methylene oxide, methylenesulﬁde, methylenesulf-
oxide, or methylenesulfone bridges locking condensed tricyclic
systems yielded some very potent 1 mimics. One of these is
(E)-29a, which carries a methylenesulﬁde bridge, is 3-fold more
potent than the parent 1 in competing for the binding to eIF4E
in the cell-free FP assay (Figure 1) with an IC50 = 15.5 μM,
disrupts very eﬀectively eIF4E/eIF4G protein−protein inter-
action and concomitantly increases very eﬀectively binding of
4E-BP1 to eIF4E (Figure 2), and last but not least is a potent
inhibitor of human melanoma CRL-2813 cells proliferation
IC50 = 5.1 μM (Table 1). Taken together, these results suggest
that the binding site on eIF4E for the 2-(4-(3,4-
dichlorophenyl)thiazol-2-yl) moiety in 1 accommodates very
nicely the fused nearly coplanar tricyclic system, which may
mimic very closely a rotamer population in 1 that binds to the
Figure 2. eIF4F complex formation disruption by (E)-29a: (a) (E)-29a displaces eIF4G from eIF4E and enhances 4E-BP1 binding in melanoma
CRL-2813 cell lysate. After incubation of CRL-2813 cells with 30 μM of each compound for 3 h, the cells lysate was then used. A cap-aﬃnity
chromatography and SDS-PAGE immunoblotting were used to detect eIF4E, eIF4G, and 4E-BP1. The eIF4E lanes shown come from the same gel
and Western blot. (b) Quantitative analysis of the eﬀect of (E)-29a and (E)-35b on complex protein levels relative to eIF4E.
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macromolecular target. Recently, NMR mapping of a solution
of N-terminal fused eIF4E and 1 and high resolution X-ray
analysis of co-crystal structures of eIF4E and 1 or some of its
analogues suggest that dissociation of eIF4E−eIF4G complex in
the presence of these inhibitors is through an allosteric
mechanism (unpublished data). It is very likely that the similar
activity proﬁles of 1 and the rigidiﬁed fused tricyclic 1 mimetic
reported here strongly suggests that the latter also share a
similar molecular mechanism. For now, we conclude that the
orientation of the phenyl in position 4 relative to the
thiazolidine ring depends on the nature of the bridge in the
fused tricyclic system, the substituents on that phenyl ring, and
interplay between the former two and the conﬁguration around
the hydrazone function. Our ongoing eﬀorts will continue to
look at optimization through rigidiﬁcation modes introducing
conformational and conﬁgurational constraints to develop
novel 1 mimetics as eﬀective molecular probes. We are
currently utilizing these optimized 1 mimetics for the direct
conﬁrmation of their allosteric mechanism of action.
■ EXPERIMENTAL SECTION
Chemistry. General. All the starting materials were obtained from
commercial sources and used as purchased. Chromatography solvents
were HPLC grade and were used without further puriﬁcation. Thin
layer chromatography (TLC) analysis was performed using Merck
silica gel 60 F-254 thin layer plates. LC-MS analyses were performed
on Waters 2695 separator module with (APCI mode) (XTerra C8 30
mm × 100 mm column) micromass ZQ employing a ﬂow rate of 0.5
mL/min and a solvent system that includes A, 0.1% v/v formic acid in
water, and B, 0.1% v/v formic acid in acetonitrile. The scan range was
m/z 100−1000. HRMS analyses were performed on Agilent
Technologies, 6120 time-of-ﬂight-LC/MS instrument employing a
linear gradient of A, 0.1% v/v FA in water, and B, 0.1% v/v TFA in
acetonitrile. Melting points were measured in open Pyrex capillaries in
MEL TEMP “Electronthermal” apparatus and are uncorrected. The
purity of tested compounds was >95% as determined by RP-HPLC on
a C18 Xbridge column (4.6 mm × 100 mm, 1 mL/min) with eﬄuents
monitored at 254 nm in Waters 2695 separator module. Solvent
system employed included a linear gradient of A, 0.1% v/v TFA in
water, and B, 0.1% v/v TFA in acetonitrile. NMR spectra were
recorded on a Varian 400 or 500 MHz spectrometers. The signal of
the deuterated solvent was used as internal reference. Chemical shifts
(δ) are given in ppm and are referenced to residual not fully
deuterated solvent signal. Coupling constants (J) are given in Hz.
Synthesis of 4-(3,4-Dichlorophenyl-1-oxo-butyric Acid (7a). AlCl3
(1.99 g, 15 mmol) was added to a solution of succinic anhydride (5 g,
50 mmol) in 1,2-dichlorobenzene (44.1 g, 3 mmol) at RT. The
reaction mixture was heated to 60 °C for 2.5 h and then inverse
quenched onto cold water (120 mL), maintaining the temperature
below 50 °C, and stirred for 30 min. Then hexane (60 mL) was added,
and the stirring continued for 2 h to aﬀord 7a as an oﬀ-white solid,
which was ﬁltered and dried under vacuum.
7a. White powder, yield 5.92 g (80%); mp 181−182 °C. 1H NMR
(DMSO-d6, 400 MHz) in ppm: δ 2.54−2.57 (t, 2H), 3.24 (t, 2H), 7.79
(d, J = 8 Hz, 1H), 7.90−7.93 (dd, J = 8 and 4 Hz, 1H), 8.12 (d, J =J =
4 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz) in ppm: δ 28.4, 33.9,
128.6, 130.4, 131.7, 136.6, 137.2, 174.3, 197.5. Purity of 100% as
determined by RP-HPLC, tR = 13.55 min (linear gradient system of
0−100% B in A for 26 min). ESI-MS calcd MW for C10H8Cl2O3,
247.07; found, m/z = 247.01 (M − H)−.
Synthesis of 4-(3,4-Dichlorophenyl)butyric Acid (8a). Pure Zn
dust (98%) (2.6 g, 40 mmol) and HgCl2, (0.18 g, 0.66 mmol) were
stirred with concentrated HCl (0.25 mL) and water (0.5 mL) for 10
min. The aqueous solution was then syringed out and the
amalgamated zinc was suspended in a mixture of water (4 mL) and
concd HCl (8 mL). To this suspension were added 7a (1.0 g, 4 mmol)
followed by toluene (8 mL) and reﬂuxed with stirring for 36 h with the
addition of concd HCl (4 mL) every 5 h. After cooling to RT, the
reaction mixture was ﬁltered and the ﬁltrate was extracted with ethyl
acetate (100 mL), dried over anhydrous Na2SO4, and concentrated
under vacuum to give the crude butyric acid (8a) as oil. It was then
chromatographed on a silica gel column using hexane−ethyl acetate
mixture (9:1 v/v) as eluent.
8a. White solid, yield 0.3 g (30%), Rf 0.4 (methanol−dichloro-
methane, 1:9, v/v); mp 61−63 °C. 1H NMR (CDCl3, 400 MHz) in
ppm: δ 1.91−1.97 (m, 2H), 2.35−2.39 (t, 2H), 2.61−2.64 (t, 2H),
7.00−7.02 (dd, J = 8 and 4 Hz, 1H), 7.26 (d, J = 4 Hz, 1H), 7.34 (d, J
= 8 Hz, 1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 26.0, 33.3, 34.2,
123.2, 125.7, 128.1, 130.5, 131.8, 141.6, 179.9. Purity of 98.4% as
determined by RP-HPLC, tR = 15.16 min (linear gradient system of
0−100% B in A for 26 min). ESI-MS calcd MW for C10H10Cl2O2,
232.98; found, m/z = 231.02 (M − H)−.
Synthesis of 6,7-Dichloro-3,4-dihydronaphthalen-1(2H)-one (9a).
Polyphosphoric acid (35 g) was heated to melt at 120 °C for 30 min.
To this was added 8a (1.2 g, 5.1 mmol) and heated further with
stirring for 10 h at 130 °C. After cooling to RT, dilution with water
(100 mL) and extraction with ethyl acetate (100 mL) yielded an
organic phase that was washed with a saturated solution of NaHCO3
(50 mL), dried over anhydrous Na2SO4, and evaporated under
vacuum. The oily residue was chromatographed on silica gel column
with hexane−ethyl acetate (98:2, v/v) to obtain 9a.
9a. White solid, yield 0.32 g (30%); mp 110−111 °C. 1H NMR
(CDCl3, 500 MHz) in ppm: δ 2.09−2.14 (m, 2H), 2.62 (t, J = 6.0 Hz,
2H), 2.89 (t, J = 6.0 Hz, 2H), 7.34 (s, 1H), 8.03 (s, 1H). 13C NMR
(CDCl3, 125 MHz) in ppm: δ 23.8, 29.0, 38.7, 129.1, 130.8, 131.5,
132.3, 137.7, 143.9, 196.3. Purity of 100% as determined by RP-HPLC,
tR = 16.79 min (linear gradient system of 0−100% of B in A for 26
min). ESI-MS calcd MW for C10H8Cl2O, 215.08; found, m/z = 214.97
[M + H]+.
Synthesis of 2-Bromo-6,7-dichloro-3,4-dihydronaphthalen-
1(2H)-one (10a). To a solution of 9a (0.1 g, 0.464 mmol) in dry
diethyl ether (5 mL) was added a solution of bromine (0.074 g, 0.464
mmol) in ether (1 mL) and stirred at RT for 30 min. The residue
obtained after the removal of the solvent under vacuum was treated
with an aqueous solution of NaHCO3 (5% w/v, 10 mL) and extracted
with dichloromethane (50 mL). The organic layer was dried over
anhydrous Na2SO4, concentrated under vacuum, and chromato-
graphed on a silica gel column with ethyl acetate−hexane mixture
(5:95, v/v) to aﬀord the pure bromide 10a.
10a. White powder, yield 0.120 g (88%); mp 128−130 °C. 1H
NMR (CDCl3, 400 MHz) in ppm: δ 2.83−2.88 (m, 2H), 3.22−3.29
(m, 2H), 4.69 (t, 1H), 7.40 (s, 1H), 8.12 (s, 1H). 13C NMR (CDCl3,
100 MHz) in ppm: δ 25.4, 31.4, 49.2, 129.6, 130.5, 130.8, 132.1, 138.8,
142.3, 188.8. Purity of 98.9% as determined by RP-HPLC, tR = 18.53
min (linear gradient system of 0−100% B in A for 26 min). ESI-MS
calcd MW for C10H7BrCl2O, 293.97; found, m/z = 292.75 (M − H)−.
Synthesis 1-(7,8-Dichloro-4,5-dihydronaphtho[1,2-d]thiazol-2-
yl)hydrazine (11a) and 8,9-Dichloro-5,6-dihydro-4aH-naphtho-
[1,2-e][1,3,4]thiadiazin-3-amine (12a). A solution of 10a (0.4 g,
1.36 mmol) and thiosemicarbazide (0.124 g, 1.36 mmol) in anhydrous
dioxane (20 mL) was heated to 80 °C for 1 h and then stirred at RT
for 48 h. The resulting precipitate was ﬁltered, washed with dioxane
(10 mL), and suspended in 2 M Na2CO3 (15 mL). The pale greenish-
yellow solid of 11a and 12a was ﬁltered, washed with water, and
separated by preparative RP-HPLC using a linear gradient system of
10−50% B in A for 25 min.
11a. Oﬀ-white solid, yield 0.150 g (39%); mp 160−162 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 2.86−2.95 (m, 4H), 7.49 (s,
1H), 7.67 (s, 1H), 9.27 (bs, 2H). 13C NMR (DMSO-d6, 100 MHz) in
ppm: δ 21.3, 27.8, 123.9, 129.0, 129.6, 130.5, 131.9, 132.0, 135.9.
Purity of 65.5% as determined by RP-HPLC, tR = 13.20 min (linear
gradient system of 0−100% B in A for 26 min). ESI-MS calcd MW for
C11H9Cl2N3S, 286.18; found, m/z = 285.95 [M + H]
+.
12a. Oﬀ-white solid, yield 0.077 g (20%); mp 214−216 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 1.73−1.84 (m, 2H), 2.77−
2.95 (m, 2H), 4.31−4.35 (m, 1H), 7.66 (s, 1H), 8.05 (s, 1H). 13C
NMR (DMSO-d6, 125 MHz) in ppm: δ 25.8, 27.1, 39.6, 127.0, 129.2,
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129.7, 130.5, 131.4, 141.6, 148.0, 164.4. Purity of 96.8% as determined
by RP-HPLC, tR = 12.44 min (linear gradient system of 0−100% B in
A for 26 min). ESI-MS calcd MW for C11H9Cl2N3S, 286.18; found, m/z
= 285.95 [M + H]+.
Synthesis of (E/Z)-2-(2-(7,8-Dichloro-4,5-dihydronaphtho[1,2-d]-
thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
13a]. A suspension of 11a (0.186 g, 0.649 mmol) in 5% (v/v) acetic
acid (7 mL) was added to 2-(o-nitrophenyl)pyruvic acid (0.135 g,
0.649 mmol) in ethanol (14 mL) and was heated at 90−100 °C for 1
h. The yellow precipitate that formed upon cooling to RT was ﬁltered,
washed with water, and dried. The crude mixture containing the two
isomers, (E)-13a and (Z)-13a, was puriﬁed on a RP-C18 FCC (100 g
cartridge, ﬂow rate = 40 mL/min) using a solvent system consisting of
A, triethylammonium bicarbonate buﬀer (50 mM, pH = 8.5), and B,
methanol. The puriﬁed isomers were precipitated from their respective
fractions following acidiﬁcation with 10% HCl and separated by
centrifugation. Repeated washes of the pellets with 5% HCl followed
by thorough washes with water and drying under vacuum yielded the
following:
(E)-13a. Yellow powder; yield 0.06 g (20%); mp 255−256 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 2.85−2.89 (m, 2H), 2.93−
2.97 (m, 2H), 4.27 (s, 2H), 7.05 (d, J = 8.0 Hz, 1H), 7.47−7.51 (m,
2H), 7.55 (s, 1H), 7.60−7.65 (m, 1H), 8.04−8.06 (m, 1H), 12.44 (bs,
1H). 13C NMR (DMSO-d6, 100 MHz) in ppm: δ 21.3, 27.7, 29.8,
123.6, 125.7, 128.5, 129.2, 129.5, 129.7, 130.5, 131.7, 134.5, 136.0,
149.6, 166.0. Purity of 100% as determined by RP-HPLC, tR = 8.37
min (linear gradient system of 50−100% B in A for 20 min).
HRMS(ESI) m/z calcd for C20H14Cl2N4O4S [M + H]
+, 477.01128;
found 477.01929.
(Z)-13a. Yellow powder; yield 0.055 g (18%); mp 254−255 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 2.73−2.80 (m, 2H), 2.88−
2.92 (m, 2H), 4.15 (s, 2H), 7.46−7.55 (m, 3H), 7.59 (s, 1H), 7.66−
7.70 (m, 1H), 8.02−8.05 (m, 1H), 12.72 (bs, 1H). 13C NMR (DMSO-
d6, 100 MHz) in ppm: δ 21.2, 27.7, 36.7, 123.9, 125.2, 128.9, 129.3,
129.8, 130.4, 132.5, 133.60, 134.2, 135.9, 149.7, 164.7. Purity of 99.2%
as determined by RP-HPLC, tR = 10.79 min (linear gradient system of
50−100% B in A for 20 min). HRMS(ESI) m/z calcd for
C20H14Cl2N4O4S [M+H]
+, 477.01128; found 477.01923.
Synthesis of 4-(2,3-Dichlorophenyl)butyric Acid (7b). A solution
of 1,2-dichlorobenzene (1.47 g, 10 mmol) in dry THF (10 mL) was
added dropwise to n-butyl lithium (4 mL, 1.8 M in hexanes) at −78 °C
under N2, and the mixture was stirred for half an hour. To the pale-
yellow reaction mixture, a solution of succinic anhydride (1.0 g, 10
mmol) in dry THF (10 mL) was added slowly (15 min) and stirred for
1 h at −78 °C. The reaction was quenched by water (20 mL) and
acidiﬁed with 5 N HCl. The organic phase obtained following
extraction with DCM (100 mL) was dried over anhydrous Na2SO4
and concentrated under vacuum to yield an oily residue which after
recrystallization in toluene aﬀorded 7b.
7b. White crystals; yield 0.74 g (30%); mp 116−118 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.81 (t, 2H), 3.20 (t, 2H), 7.25−7.29
(m, 1H), 7.34−7.36 (m, 1H), 7.53−7.55 (m, 1H). 13C NMR (CDCl3,
100 MHz) in ppm: δ 28.4, 37.6, 126.9, 127.9, 132.4, 134.3, 141.4,
178.7, 200.8. Purity of 99.4% as determined by RP-HPLC, tR = 12.76
min (linear gradient system of 0−100% B in A for 26 min). ESI-MS
calcd MW for C10H8Cl2O3, 247.07; found, m/z = 244.96 [M + H]
+.
Synthesis of 5,6-Dichloro-3,4-dihydronaphthalen-1(2H)-one (9b).
Step A. Pure Zn dust (98%) (4.0 g, 61 mmol) and HgCl2, (0.4 g, 1.4
mmol) were stirred with concd HCl (0.25 mL) and water (6.6 mL) for
10 min. The aqueous solution was removed, and the zinc amalgam was
then suspended in water (2.5 mL) and concd HCl (6 mL). The stirred
suspension was treated with 7b (2.3 g, 9.3 mmol) and toluene (3.5
mL) and reﬂuxed for 24 h with the addition of concd HCl (2 mL) in
every 6 h. The reaction mixture was cooled to RT and ﬁltered, and the
ﬁltrate was extracted with ethyl acetate (100 mL). The ethyl acetate
fraction was dried over anhydrous Na2SO4 and concentrated under
vacuum to give 8b as white solid.
8b. White solid; yield 1.2 g (57%). Purity of 99.2% as determined
by RP-HPLC, tR = 15.01 min (linear gradient system of 0−100% B in
A for 26 min). ESI-MS calcd MW for C10H10Cl2O2, 233.09; found, m/z
= 230.74 (M − H)−.
Step B. 8b (1.2 g, 5.1 mmol) was added to a polyphosphoric acid
melt (35 g) at 130 °C and stirred for 10 h. The reaction mixture was
cooled to RT, and water (100 mL) was added. This mixture was
extracted with ethyl acetate (100 mL) and washed with saturated
solution of NaHCO3 (50 mL). The organic phase was dried over
anhydrous Na2SO4 and concentrated in vacuum. The oily residue was
subjected to silica gel column chromatography with hexane−ethyl
acetate mixture (98:2 v/v) to obtain pure 9b.
9b. Pale-yellow solid; yield 0.32 g (30%); mp 95−96 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.12−2.17 (m, 2H), 2.59−2.62 (t, 2H),
3.01−3.04 (t, 2H), 7.38 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H).
13C NMR (CDCl3, 100 MHz) in ppm: δ 22.3, 28.1, 38.0, 126.4, 128.4,
128.5, 132.6, 138.5, 143.9, 196.7. Purity of 98.3% as determined by RP-
HPLC, tR = 16.90 min (linear gradient system of 0−100% B in A for
26 min). ESI-MS calcd MW for C10H8Cl2O, 215.08; found, m/z =
214.91 [M + H]+.
Synthesis of 2-Bromo-5,6-dichloro-3,4-dihydronaphthalen-
1(2H)-one (10b). Synthesis of 10b followed the identical procedure
as described for 10a.
10b. White powder; yield 0.13 g (90%); mp 102−103 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.49−2.59 (m, 2H), 3.16−3.19 (m,
2H), 4.67−4.69 (m, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 8.0 Hz,
1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 24.9, 30.6, 48.6, 127.7,
129.0, 132.5, 139.5, 142.5, 189.3. Purity of 98.4% as determined by RP-
HPLC, tR = 18.58 min (linear gradient system of 0−100% B in A for
26 min). ESI-MS calcd MW for C10H7BrCl2O, 293.37; found, m/z =
294.84 (M + H)+.
Synthesis of 1-(8,9-Dichloro-4,5-dihydronaphtho[1,2-d]thiazol-2-
yl)hydrazine (11b) and 9,10-Dichloro-5,6-dihydro-4aH-naphtho-
[1,2-e][1,3,4]thiadiazin-3-amine (12b). Synthesis of 11b and 12b
followed the identical procedure as described for 11a and 12a adjusted
to 0.085 mmol scale for the 10b and thiosemicarbazide. Both 11b and
12b were puriﬁed on a RP-C18 FCC (100 g cartridge, ﬂow rate = 40
mL/min) using 0−40% B in A in 2 h.
11b. Oﬀ-white solid; yield 0.092 g (38%); mp 197−199 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 2.88−2.95 (m, 2H), 3.09−
3.15 (m, 2H), 7.53 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 9.74
(bs, 2H). 13C NMR (DMSO-d6, 100 MHz) in ppm: δ 20.9, 26.7,
122.6, 123.0, 129.1, 130.3, 131.0, 131.9, 134.9, 143.1, 168.2. Purity of
85.7% as determined by RP-HPLC, tR = 13.39 min (linear gradient
system of 0−100% B in A for 26 min). ESI-MS calcd MW for
C11H9Cl2N3S, 286.18; found, m/z = 283.94 (M − H)−.
12b. Oﬀ-white solid; yield 0.051 g (21%); mp 213-215 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 1.83−1.90 (m, 2H), 2.79−
2.85 (m, 2H), 3.19−3.23 (m, 2H), 4.31−4.35 (m, 1H), 7.62 (d, J = 5.0
Hz, 1H), 7.99 (d, J = 5.0 Hz, 1H). 13C NMR (DMSO-d6, 125 MHz) in
ppm: δ 25.5, 26.1, 34.0, 125.6, 129.5, 129.7, 131.6, 135.1, 140.6, 148.5.
Purity of 98.7% as determined by RP-HPLC, tR = 12.7 min (linear
gradient system of 0−100% B in A for 26 min). ESI-MS calcd MW for
C11H9Cl2N3S, 286.18; found, m/z = 283.94 (M − H)−.
Synthesis of (E/Z)-2-(2-(6,7-Dichloro-4,5-dihydronaphtho[1,2-d]-
thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
13b]. Synthesis of (E)-13b and (Z)-13b followed the identical
procedure as described for (E)-13a and (Z)-13a adjusted to 0.0454
mmol scale for the 11b and 2-(o-nitrophenyl)pyruvic acid.
(E)-13b. Yellow powder; yield 0.061 g (28%); mp 254−255 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 2.92−2.97(m, 2H), 3.11−3.15
(m, 2H), 4.20 (s, 2H), 7.05−7.08 (m, 1H), 7.45−7.50 (m, 3H), 7.62−
7.68 (m, 1H), 8.04−8.07 (m, 1H), 12.3 (bs, 1H). 13C NMR (DMSO-
d6, 125 MHz) in ppm: δ 20.9, 26.6, 29.8, 122.2, 125.7, 128.4, 129.1,
129.5, 130.3, 131.0, 131.8, 134.5, 135.0, 149.7, 166.1. Purity of 98.7%
as determined by RP-HPLC, tR = 8.69 min (linear gradient system of
50−100% B in A for 20 min). HRMS(ESI) m/z calcd for
C20H14Cl2N4O4S [M+H]
+, 477.01128; found 477.01951.
(Z)-13b. Yellow powder; yield 0.036 g (17%); mp 261−262 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 2.84 (t, 2H), 3.06 (t, 2H),
4.15 (s, 2H), 7.44 (d, J = 5 Hz, 1H), 7.49−7.55 (m, 3H), 7.67−7.70
(m, 1H), 8.03−8.05 (m, 1H), 12.70 (bs, 1H). 13C NMR (DMSO-d6,
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125 MHz) in ppm: δ 20.9, 26.5, 36.7, 122.5, 125.2, 128.8, 129.0, 130.4,
130.9, 132.5, 134.1, 134.8, 149.7, 164.7. Purity of 100% as determined
by RP-HPLC, tR = 11.39 min (linear gradient system of 50−100% B in
A for 20 min). HRMS(ESI) m/z calcd for C20H14Cl2N4O4S [M+H]
+,
477.01128; found 477.01961.
Synthesis of 3-(2,3-Dichlorophenoxy)propanoic Acid (15). Ox-
etan-2-one (0.72 g, 10 mmol) was added dropwise (5 min) to a
solution of 2,3-dichlorophenol, 14 (1.63 g, 10 mmol) in 0.25 M
NaOH (4 mL) and stirred overnight at 100 °C. After cooling to RT,
the reaction mixture was diluted with water (10 mL), acidiﬁed with
concd HCl (2 mL), and extracted with diethyl ether (2 × 20 mL). The
combined organic phases were washed with 10% (w/v) NaHCO3 (100
mL). The solid 15 obtained upon acidiﬁcation of the aqueous layer to
pH = 2 with concd HCl was ﬁltered, washed thoroughly with water,
and dried under vacuum.
15. White solid; yield 1.0 g (42%); mp 147−150 °C. 1H NMR
(CD3OD, 400 MHz) in ppm: δ 2.00 (t, 2H), 4.28 (t, 2H), 6.98−7.00
(m, 1H), 7.06−7.08 (m, 1H), 7.17−7.21 (m, 1H). 13C NMR
(CD3OD, 100 MHz) in ppm: δ 33.9, 65.2, 111.6, 121.4, 122.2, 127.7,
133.3, 155.8, 173.3. Purity of 91.1% as determined by RP-HPLC, tR =
13.74 min (linear gradient system of 0−100% B in A for 26 min). ESI-
MS calcd MW for C9H8Cl2O3, 235.06; found, m/z = 232.84 (M − H)−.
Synthesis of 3-(3,4-Dichlorophenoxy)propanoic Acid (18). A
solution of 3,4-dichlorophenol, 17 (1.63 g, 10 mmol) in DMF (5
mL) was added dropwise (5 min) to a stirred suspension of NaH (0.4
g of 60% suspension in mineral oil, 10 mmol) in dry DMF (10 mL)
and stirred for 30 min at RT and heated for 1 h at 100 °C. Then
oxetan-2-one (0.72 g, 10 mmol) was added dropwise (5 min) and
stirred overnight. After cooling to RT, it was diluted with water (10
mL), acidiﬁed with concd HCl (2 mL), and extracted with diethyl
ether (2 × 20 mL). The combined organic phases were extracted with
10% (w/v) NaHCO3 (100 mL). The solid 18 obtained upon
acidiﬁcation of the aqueous phase to pH = 2 with (10 mL) was ﬁltered,
washed thoroughly with water, and dried under vacuum.
18. White solid; yield 1.2 g (50%); mp 114−116 °C. 1H NMR
(CD3OD, 400 MHz) in ppm: δ 2.74 (t, 2H), 4.19 (t, 2H), 6.83−6.86
(m, 1H), 7.06 (d, J = 4.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H). 13C NMR
(CD3OD, 100 MHz) in ppm: δ 33.9, 64.3, 114.7, 116.3, 123.6, 130.6,
132.5, 158.2, 173.4. Purity of 88.6% as determined by RP-HPLC, tR =
14.29 min (linear gradient system of 0−100% B in A for 26 min). ESI-
MS calcd MW for C9H8Cl2O3, 235.06; found, m/z = 232.87 (M − H)−.
Synthesis of 7,8-Dichloro-2,3-dihydrochromen-4-one (16) and
6,7-Dichloro-2,3-dihydrochromen-4-one (19). Method A. Warning!
This reaction was carried out in a dedicated HF-reaction apparatus
type I following strict adherence to the manufacturer’s instruction. A
suspension of 15 or 18 (0.5 g, 2.12 mmol) in liquid HF (50 mL) was
allowed to stir overnight at RT. The residue obtained after removing
the HF under vacuum was dissolved in ether (50 mL) and washed
with 10% (w/v) NaHCO3 (50 mL), and the separated organic phase
was dried over anhydrous MgSO4 to yield 16 or 19.
Method B. 15 or 18 (0.5 g, 2.12 mmol) was stirred in Eaton’s
Reagent (20 mL) at RT for 1 h followed by 5 h at 70 °C. The dark-red
reaction mixture was cooled to RT and quenched into ice-cold water
(100 mL) and left for 30 min. The precipitate obtained from 15 was
ﬁltered and dried under vacuum to aﬀord 16. The reaction of 18
yielded a precipitate containing a mixture of 19 and 20, was dried
under vacuum and puriﬁed by FCC on a silica gel column employing
ethyl acetate−hexane mixture (2:8, v/v) to obtain pure 19 and 20.
16. Oﬀ-white solid; yield 0.350 g (76%, method A), 0.4 g (80%,
method B); mp 90−92 °C. 1H NMR (CDCl3, 400 MHz) in ppm: δ
2.82 (t, 2H), 4.65 (t, 2H), 7.10 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz,
1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 37.2, 68.2, 120.8, 122.0,
122.9, 125.6, 140.5, 158.5, 190.2. Purity of 99.8% as determined by RP-
HPLC, tR = 14.99 min (linear gradient system of 0−100% B in A for
26 min).
19. Oﬀ-white solid; yield 0.350 g (76%, method A), 0.125 g (27%,
method B); mp 131−133 °C. 1H NMR (CDCl3, 400 MHz) in ppm: δ
2.79 (t, 2H), 4.52 (t, 2H), 7.10 (s, 1H), 7.90 (s, 1H). 13C NMR
(CDCl3, 100 MHz) in ppm: δ 37.4, 67.6, 118.0, 120.2, 120.9, 126.0,
128.3, 140.0, 160.3, 189.9. Purity of 94.6% as determined by RP-
HPLC, tR = 15.69 min (linear gradient system of 0−100% B in A for
26 min).
20. Oﬀ-white solid; yield 0.175 g (38%, method B); mp 111−114
°C. 1H NMR (CDCl3, 500 MHz) in ppm: δ 2.82−2.84 (m, 2H),
4.50−4.52 (m, 2H), 6.87 (d, 1H, J = 8.5 Hz), 7.47 (d, 1H, J = 8.5 Hz).
13C NMR (CDCl3, 125 MHz) in ppm: δ 38.8, 67.0, 118.0, 119.9,
127.7, 132.3, 135.6, 161.9, 189.1. Purity of 99.5% as determined by RP-
HPLC, tR = 15.54 min (linear gradient system of 0−100% B in A for
26 min).
Synthesis of 3-Bromo-7,8-dichloro-2,3-dihydrochromen-4-one
(21a) and 3-Bromo-6,7-dichloro-2,3-dihydrochromen-4-one (21b).
Pyridinium bromide perbromide (0.147 g, 0.46 mmol) was added to a
solution of 16 or 19 (0.1 g, 0.46 mmol) in a mixture of anhydrous
ethanol and chloroform (1:1 v/v, 10 mL) during 10 min. The reddish-
brown mixture was stirred at 50 °C for 30 min and cooled to RT. The
residue obtained after removal of solvent under vacuum was
suspended in water (20 mL) and extracted with dichloromethane
(20 mL). The organic phase was washed with 5% (w/v) NaHCO3 (20
mL) followed by water (20 mL), dried over anhydrous Na2SO4, and
concentrated under vacuum. The crude mixture was puriﬁed by FCC
using hexane−ethyl acetate (9:1, v/v) solvent mixtures to yield pure
21a and 21b.
21a. Pale-yellow solid; yield 0.1 g (74%); mp 134−136 °C. 1H
NMR (CDCl3, 400 MHz) in ppm: δ 4.62−4.64 (m, 1H), 4.75−4.80
(m, 2H), 7.20 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H). 13C NMR
(CDCl3, 100 MHz) in ppm: δ 44.0, 72.2, 118.2, 122.2, 123.9, 126.6,
141.5, 157.3, 184.0. Purity of 97.5% as determined by RP-HPLC, tR =
12.29 min (linear gradient system of 30−100% B in A for 26 min).
ESI-MS calcd MW for C9H5BrCl2O2, 295.94; found, m/z = 294.84 (M
− H)−.
21b. White powder; yield 0.104 g, (76%); mp 100−107 °C. 1H
NMR (CDCl3, 400 MHz) in ppm: δ 4.59−4.66 (m, 3H), 7.20 (s, 1H),
7.98 (s, 1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 44.3, 71.7,
118.4, 120.2, 127.1, 129.3, 141.1, 159.0, 183.5. Purity of 98.4% as
determined by RP-HPLC, tR = 11.61 min (linear gradient system of
30−100% B in A for 26 min). ESI-MS calcd MW for C9H5BrCl2O2,
295.94; found, m/z = 294.02 (M − H)−.
Synthesis of (E/Z)-2-(2-(6,7-Dichloro-4H-chromeno[4,3-d]thiazol-
2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-23a]. Step
A. A solution of 21a (0.2 g, 0.67 mmol) and thiosemicarbazide (0.07 g,
0.67 mmol) in anhydrous dioxane (20 mL) was stirred at 60 °C for 24
h. The precipitate formed after cooling to RT was ﬁltered, washed with
dioxane (10 mL), and suspended in 2 M Na2CO3 (20 mL). The
brown product was ﬁltered, washed with water, and dried to yield
crude 22a and used as such in the next step.
22a. Yield 0.08 g (39%). ESI-MS calcd MW for C10H7Cl2N3OS,
288.15; found, m/z = 291.94 (M + H)+.
Step B. Synthesis of (E)-23a and (Z)-23a followed the identical
procedure as described for (E)-13a and (Z)-13a adjusted to 0.27
mmol scale for the 22a and 2-(o-nitrophenyl)pyruvic acid.
(E)-23a. Pale-brown ﬂuﬀy solid; yield 0.028 g (22%); mp 252−253
°C. 1H NMR (DMSO-d6, 400 MHz) in ppm: δ 4.27 (s, 2H), 5.55 (s,
2H), 7.05 (d, 1H, J = 4 Hz), 7.19 (d, 1H, J = 8 Hz), 7.33 (d, 1H, J = 8
Hz), 7.49−7.51 (m, 1H), 7.61−7.65 (m, 1H), 8.05 (d, 1H, J = 8
Hz),12.40 (bs, 1H). 13C NMR (DMSO-d6, 100 MHz) in ppm: δ 29.9,
66.3, 119.8, 121.4, 123.5, 125.7, 128.5, 129.5, 131.4, 131.6, 134.5,
149.6, 150.7, 165.9. Purity of 99.5% as determined by RP-HPLC, tR =
11.60 min (linear gradient system of 30−100% B in A for 20 min).
HRMS(ESI) m/z calcd for C19H12Cl2N4O5S [M+H]
+, 478.99054;
found 479.00179.
(Z)-23a. Bright-yellow ﬂuﬀy solid; yield 0.016 g (12%); mp 253−
254 °C. 1H NMR (DMSO-d6, 500 MHz) in ppm: δ 4.17 (s, 2H), 5.47
(s, 2H), 7.18−7.20 (m, 1H), 7.40 (d, 1H, J = 5 Hz), 7.51−7.56 (m,
2H), 7.68−7.71 (m, 1H), 8.05 (d, 1H, J = 5 Hz), 12.72 (bs, 1H). 13C
NMR (DMSO-d6, 125 MHz) in ppm: δ 36.8, 66.2, 119.7, 121.8, 123.5,
125.3, 128.9, 131.5, 132.4, 133.7, 134.2, 149.6, 150.6, 164.7. Purity of
100% as determined by RP-HPLC, tR = 13.60 min (linear gradient
system of 30−100% B in A for 20 min). HRMS(ESI) m/z calcd for
C19H12Cl2N4O5S [M+H]
+, 478.99054; found 479.02029.
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Synthesis of (E/Z)-2-(2-(7,8-Dichloro-4H-chromeno[4,3-d]thiazol-
2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-23b]. Step
A. Synthesis of 22b followed the identical procedure as described for
22a.
22b. Yield 0.11 g (57%). ESI-MS calcd MW for C10H7Cl2N3OS,
288.15; found, m/z = 291.88 (M + H)+.
Step B. Synthesis of (E)-23b and (Z)-23b followed the identical
procedure as described for (E)-13a and (Z)-13a adjusted to 0.48
mmol scale for 22b and 2-(o-nitrophenyl)pyruvic acid.
(E)-23b. Yellow powder; yield 0.055 g (24%); mp 260−261 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 4.28 (s, 2H), 5.45 (s, 2H),
7.06 (d, J =5.0 Hz, 1H), 7.17 (s, 1H), 7.43 (s, 1H), 7.50 (t, 1H), 7.64
(t, 1H), 8.05 (d, J =10.0 Hz, 1H). 13C NMR (DMSO-d6, 125 MHz) in
ppm: δ 30.0, 65.6, 118.8, 123.2, 124.2, 125.7, 128.5, 129.6, 130.6,
131.7, 134.5, 149.6, 152.9, 165.9. Purity of 98.0% as determined by RP-
HPLC, tR = 12.77 min (linear gradient system of 30−100% B in A for
20 min). HRMS(ESI) m/z calcd for C19H12Cl2N4O5S [M+H]
+,
478.99054; found 478.99796.
(Z)-23b. Yellow powder; yield 0.037 g (16%); mp 265−266 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 4.17 (s, 2H), 5.38 (s, 2H),
7.16 (s, 1H), 7.51−7.56 (m, 3H), 7.69 (s, 1H), 8.04 (d, J =10.0 Hz,
1H). 13C NMR (DMSO-d6, 125 MHz) in ppm: δ 36.8, 65.5, 118.7,
123.6, 124.3, 125.2, 129.0, 130.7, 132.4, 133.7, 134.2, 149.6, 152.8,
164.6. Purity of 99.5% as determined by RP-HPLC, tR = 14.74 min
(linear gradient system of 30−100% B in A for 20 min). HRMS(ESI)
m/z calcd for C19H12Cl2N4O5S [M+H]
+, 478.99054; found 478.99785.
Synthesis of 3-(3,4-Dichlorophenylthio)propanoic Acid (25a) and
3-(2,3-Dichlorophenylthio)propanoic Acid (25b). An ice-cold
mixture consisting of 3-bromopropionic acid (2.12 g, 13.6 mmol)
and Na2CO3 (1.172 g, 13.6 mmol) dissolved in water (10 mL) was
added dropwise to a solution of either 3,4-dichlorobenzenethiol or 2,3-
dichlorobenzenethiol (2.5 g, 13.6 mmol) in aqueous 2N NaOH
solution (6 mL) and ethanol (2 mL). This reaction mixture was heated
at 100 °C for 4 h, cooled to RT, and extracted with ether. The
precipitate formed after acidiﬁcation of the aqueous portion with ice-
cold 3 N HCl to pH = 2 followed by cooling to 0 °C for 30 min was
ﬁltered oﬀ and dried to give either 25a or 25b.
25a. White solid; yield 3.0 g (88%); mp 70−72 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.68 (t, 2H, J = 8 Hz), 3.15 (t, 2H, J = 8
Hz), 7.16−7.18 (m, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.41−7.43 (m, 1H),
11.40 (bs, 1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 28.9, 34.2,
129.3, 130.9, 131.1, 131.4, 133.2, 135.6, 178.1. Purity of 99.3% as
determined by RP-HPLC, tR = 15.33 min (linear gradient system of
0−100% B in A for 26 min). ESI-MS calcd MW for C9H8Cl2O2S,
251.13, found: m/z = 249.01 (M − H)−.
25b. Oﬀ-white solid; yield 2.8 g (82%); mp 139−142 °C. 1H NMR
(CDCl3, 500 MHz) in ppm: δ 2.61 (t, 2H), 3.20 (t, 2H), 7.31−7.36
(m, 1H), 7.39−7.42 (m, 1H), 12.43 (s, 1H). 13C NMR (CDCl3, 125
MHz) in ppm: δ 27.4, 33.6, 125.8, 127.2, 129.0, 129.2, 132.8, 139.2,
173.1. Purity of 95.6% as determined by RP-HPLC, tR = 14.96 min
(linear gradient system of 0−100% B in A for 26 min). ESI-MS calcd
MW for C9H8Cl2O2S, 251.13; found, m/z = 250.57 (M − H)−.
Synthesis of 6,7-Dichlorothiochroman-4-one (26a) and 7,8-
Dichlorothiochroman-4-one (26b). Ketones 25a or 25b (2.8 g,
11.1 mmol) were added portionwise to stirred concd H2SO4 (50 mL),
previously cooled to −10 °C, and warmed to RT and left stand for 2 h.
The dark-red reaction mixture was poured slowly over ice-cold water
(400 mL) and kept aside for 1 h to form a white precipitate. Pure 26a
and 26b were obtained after recrystallization from ethanol.
26a. White crystals; yield 2.0 g (77%); mp 143−146 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.92 (m, 2H), 3.21−3.25 (m, 2H), 7.36
(s, 1H), 8.10 (s, 1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 26.8,
39.1, 129.1, 129.8, 130.3, 130.7, 138.1, 141.8, 192.2. Purity of 100% as
determined by RP-HPLC, tR = 17.33 min (linear gradient system of
0−100% B in A for 26 min). ESI-MS calcd MW for C9H6Cl2OS,
233.11; found, m/z = 232.81 and 234.83 (M + H)+.
26b. Oﬀ-white solid; yield 2.3 g (88%); mp 112−115 °C. 1H NMR
(CDCl3, 500 MHz) in ppm: δ 2.87 (m, 2H), 3.37 (m, 2H), 7.42−7.45
(m, 1H), 7.87−7.89 (m, 1H). 13C NMR (CDCl3, 125 MHz) in ppm: δ
26.0, 37.8, 126.4, 128.5, 128.7, 131.4, 137.5, 144.3, 192.9. Purity of
99.1% as determined by RP-HPLC, tR = 16.88 min (linear gradient
system of 0−100% B in A for 26 min). ESI-MS calcd MW for
C9H6Cl2OS, 233.11; found, m/z = 232.81 and 234.83 (M + H)
+.
Synthesis of 3-Bromo-6,7-dichloro-2,3-dihydrothiochromen-4-
one (27a) and 3-Bromo-7,8-dichloro-2,3-dihydrothiochromen-4-
one (27b). To a solution of (0.5 g, 2.14 mmol) 26a or 26b dissolved
in dry chloroform (20 mL) was added dropwise a solution of bromine
(0.342 g, 2.14 mmol) in chloroform (5 mL). The reaction mixture was
stirred at RT for 2 h and then at 60 °C for 1 h. It was then cooled to
RT and extracted with 10% (w/v) Na2S2O3 solution (25 mL). The
organic phase was washed with water (50 mL), dried over anhydrous
Na2SO4, ﬁltered, and concentrated under vacuum to give crude
bromide. It was subjected to silica gel FCC using hexane−ethyl acetate
(9:1, v/v) solvent mixture to yield pure 27a and 27b.
27a. Oﬀ-white solid; yield 0.4 g (60%); mp 128−131 °C. 1H NMR
(CDCl3, 500 MHz) in ppm: δ 3.44−3.48 (m, 1H), 3.67−3.70 (m,
1H), 4.90−4.92 (m, 1H), 7.40 (s, 1H), 8.18 (s, 1H). 13C NMR
(CDCl3, 125 MHz) in ppm: δ 35.0, 48.2, 128.8, 130.6, 132.0, 139.0,
140.6, 185.4. Purity of 98.4% as determined by RP-HPLC, tR = 18.61
min (linear gradient system of 0−100% B in A for 26 min).
27b. Oﬀ-white solid; yield 0.461 g (69%); mp 104−106 °C. 1H
NMR (CDCl3, 500 MHz) in ppm: δ 3.47−3.54 (m, 1H), 3.67−3.71
(m, 1H), 4.90−4.92 (m, 1H), 7.31 (d, 1H), 8.01 (d, 1H). 13C NMR
(CDCl3, 125 MHz) in ppm: δ 34.6, 47.6, 126.7, 128.2, 129.5, 139.5,
142.9, 185.9. Purity of 99.1% as determined by RP-HPLC, tR = 18.23
min (linear gradient system of 0−100% B in A for 26 min).
Synthesis of (E/Z)-2-(2-(7,8-Dichloro-4H-thiachromeno[4,3-d]-
thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
29a]. Step A. A solution of 27a (0.5 g, 1.6 mmol) and
thiosemicarbazide (0.145 g, 1.6 mmol) in anhydrous dioxane (20
mL) was stirred at RT for 24 h and then heated to 80 °C for 12 h. The
reaction mixture was then cooled to RT, and the precipitate was
ﬁltered, washed with dioxane (20 mL), and dried. The solid was
triturated with 2 M Na2CO3 (40 mL), ﬁltered, thoroughly washed with
water, and dried to yield 28a, which was used as such in the next step.
28a. Yield 0.304 g (62%). ESI-MS calcd MW for C10H7Cl2N3S2,
304.22; found, m/z = 303.92 and 305.94 (M + H)+.
Step B. A suspension of 28a (0.304 g, 1 mmol) in 5% (v/v) acetic
acid (7 mL) was added to 2-(o-nitrophenyl)pyruvic acid (0.209 g, 1
mmol) in ethanol (14 mL) and was heated at 90−100 °C for 2 h. The
yellow precipitate that formed upon cooling to RT was ﬁltered, washed
with water, and dried. The crude mixture containing the two isomers,
(E)-29a and (Z)-29a, were puriﬁed on a RP-C18 FCC (100 g cartridge,
ﬂow rate = 40 mL/min) using a linear gradient of 0−60% B in A for 3
h (A, triethylammonium bicarbonate buﬀer (50 mM, pH = 8.5), and
B, methanol). The puriﬁed isomers were precipitated from their
respective pooled fractions following acidiﬁcation with 10% (v/v) HCl
to pH = 2 and separated by centrifugation. The pellets were washed
consecutively with 5% (v/v) HCl and water and dried under vacuum
to yield the following:
(E)-29a. Brown powder; yield 0.096 g (20%); mp 259−260 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 4.26 (s, 2H), 4.28 (s, 2H),
7.06 (d, J =10.0 Hz, 1H), 7.48−7.52 (m, 1H), 7.51 (s, 1H), 7.58−7.66
(m, 1H), 7.69 (s, 1H), 8.06 (d, 1H), 12.10 (bs, 1H), 12.77 (bs, 1H).
13C NMR (DMSO-d6, 125 MHz) in ppm: δ 23.8, 29.9, 125.7, 128.5,
128.7, 128.8, 129.5, 130.2, 131.6, 132.1, 134.5, 149.6, 165.9. Purity of
99.2% as determined by RP-HPLC, tR = 10.33 min (linear gradient
system of 50−100% B in A for 20 min). HRMS(ESI) m/z calcd for
C19H12Cl2N4O4S2 [M+H]
+, 494.96770; found 494.97625.
(Z)-29a. Brown powder; yield 0.035 g (7%); mp 230−231 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 4.15 (s, 2H), 4.17 (s, 2H),
7.49−7.56 (m, 3H), 7.66−7.72 (m, 2H), 8.03 (d, J = 8 Hz, 1H), 12.66
(bs, 1H). 13C NMR (DMSO-d6, 100 MHz) in ppm: δ 23.7, 36.8,
125.2, 125.9, 128.6, 128.9, 130.3, 132.0, 132.4, 133.6, 134.2, 149.7,
164.7. Purity of 99.8% as determined by RP-HPLC, tR = 13.33 min
(linear gradient system of 50−100% B in A for 20 min). HRMS(ESI)
m/z calcd for C19H12Cl2N4O4S2 [M+H]
+, 494.96770; found
494.97396.
Synthesis of (E/Z)-2-(2-(6,7-Dichloro-4H-thiachromeno[4,3-d]-
thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
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29b]. Step A. Synthesis of 28b followed the identical procedure as
described for 28a.
28b. Yield 0.280 g (57%). ESI-MS calcd MW for C10H7Cl2N3S2,
304.22; found, m/z = 303.92 and 305.94 (M + H)+.
Step B. Synthesis of (E)-29b and (Z)-29b followed the identical
procedure as described for (E)-29a and (Z)-29a adjusted to 0.82
mmol scale for the 28a and 2-(o-nitrophenyl)pyruvic acid.
(E)-29b. Orange powder; yield 0.090 g (22%); mp 225−226 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 4.27 (s, 2H), 4.32 (s, 2H),
7.05 (d, J = 8 Hz, 1H), 7.39 (d, J = 8 Hz, 1H), 7.47−7.52 (m, 1H),
7.59−7.68 (m, 2H), 8.05 (d, J = 8 Hz, 1H), 12.21 (s, 1H), 12.74 (s,
1H). 13C NMR (DMSO-d6, 100 MHz) in ppm: δ 24.2, 29.9, 124.2,
125.7, 127.5, 128.5, 129.5, 131.1, 131.7, 134.5, 148.5, 149.6, 166.0.
Purity of 99.9% as determined by RP-HPLC, tR = 15.66 min (linear
gradient system of 30−100% B in A for 20 min). HRMS(ESI) m/z
calcd for C19H12Cl2N4O4S2 [M+H]
+, 494.96770; found 494.97248.
(Z)-29b. Pale-brown powder; yield 0.035 g (9%); mp 229−230 °C.
1H NMR (DMSO-d6, 400 MHz) in ppm: δ 4.15 (s, 2H), 4.24 (s, 2H),
7.36−7.39 (m, 1H), 7.49−7.55 (m, 2H), 7.61−7.64 (m, 1H), 7.67−
7.70 (m, 1H), 8.03 (d, J = 7.6 Hz, 1H), 12.65 (s, 1H). 13C NMR
(DMSO-d6, 100 MHz) in ppm: δ 24.1, 36.8, 124.5, 125.2, 127.4, 128.3,
128.9, 130.4, 131.2, 132.4, 133.6, 134.2, 149.7, 164.7. Purity of 99.4%
as determined by RP-HPLC, tR = 18.23 min (linear gradient system of
50−100% B in A for 20 min). HRMS(ESI) m/z calcd for
C19H12Cl2N4O4S2 [M+H]
+, 494.96770; found 494.97512.
Synthesis of 3-Bromo-6,7-dichlorothiochroman-4-one 1-oxide
(30a) and 3-Bromo-7,8-dichloro-2,3-dihydrothiochromen-4-one-1-
oxide (30b). A solution of m-chloroperbenzoic acid (0.287 g, 1.72
mmol) in chloroform (10 mL) was added dropwise to a solution of
27a or 27b (0.4 g, 1.72 mmol) in chloroform (10 mL) over a period of
30 min. The resultant mixture was stirred at RT for 90 min and treated
with saturated NaHCO3 solution (20 mL). The separated organic
phase was washed with water (50 mL), dried over anhydrous Na2SO4,
ﬁltered, and evaporated under vacuum to yield 30a or 30b,
respectively.
30a. White solid; yield 0.428 g (76%); mp 201−202 °C. Purity of
96.9% as determined by RP-HPLC, tR = 7.37 min (linear gradient
system of 30−100% B in A for 26 min). ESI-MS calcd MW for
C9H5BrCl2O2S, 328.01; found, m/z = 326.87 (M − H)−.
30b. White solid; yield 0.430 g (76%); mp 211−212 °C. 1H NMR
(DMSO-d6, 500 MHz) in ppm: δ 4.19 (dd, 1H, J1 = 4 Hz, J2 = 14 Hz),
4.31 (t, 1H, J = 14 Hz), 6.11 (dd, 1H, J1 = 4 Hz, J2 = 13 Hz), 8.06 (s,
2H). 13C NMR (DMSO-d6, 100 MHz) in ppm: δ 44.8, 52.2, 129.8,
130.3, 133.8, 135.0, 139.3, 142.8, 186.5. Purity of 92.2% as determined
by RP-HPLC, tR = 11.74 min (linear gradient system of 0−100% B in
A for 26 min). ESI-MS calcd MW for C9H5BrCl2O2S, 328.01; found,
m/z = 326.74 (M − H)−.
Synthesis of (E/Z)-2-(2-(7,8-Dichloro-5-oxido-4H-thiochromeno-
[4,3-d]thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/
Z)-32a]. Step A. A solution of 30a (0.380 g, 1.15 mmol) and
thiosemicarbazide (0.105 g, 1.15 mmol) in anhydrous dioxane (20
mL) was stirred at RT for 24 h and then heated at 70 °C for 24 h. The
mixture was cooled to RT, and the resulting precipitate was ﬁltered,
washed with dioxane (20 mL), and dried. The solid was triturated with
2 M Na2CO3 (40 mL), ﬁltered, washed with water, and dried under
vacuum to yield the crude 31a.
31a. Yield 0.240 g (65%). ESI-MS calcd MW for C10H7Cl2N3OS2,
320.22; found, m/z = 321.83 (M + H)+.
Step B. To a suspension of 31a (0.186 g, 0.581 mmol) in acetic acid
(10 mL) was added 2-(o-nitrophenyl)pyruvic acid (0.121 g, 0.581
mmol). The reaction mixture was stirred at RT for 2 h and diluted
with water (20 mL), forming a brown precipitate that was ﬁltered,
washed with water (40 mL), and dried. The crude mixture of the two
isomers, (E)-32a and (Z)-32a, were puriﬁed on a RP-C18 FCC (100 g
cartridge, ﬂow rate = 40 mL/min) using a linear gradient system of 0−
100% of B in A for 3h (A, water, and B, methanol).
(E)-32a. Brown ﬂuﬀy solid; yield 0.044 g (17%) mp: 204−206 °C.
1H NMR (DMSO-d6, 400 MHz) in ppm: δ 4.30 (s, 2H), 4.35 (d, 1H, J
= 16.0 Hz), 4.80 (d, 1H, J = 16.0 Hz), 7.08 (d, 1H, J = 8.0 Hz), 7.48−
7.52 (m, 1H), 7.62−7.66 (m, 1H), 7.89 (s, 1H), 8.06 (d, 1H, J = 8.0
Hz), 8.14 (s, 1H), 12.26−12.95 (m, 2H). 13C NMR (DMSO-d6, 100
MHz) in ppm: δ 30.0, 45.1, 125.7, 126.4, 128.5, 129.7, 131.0, 131.9,
134.5, 136.1, 136.9, 149.7, 165.8. Purity of 96.5% as determined by RP-
HPLC, tR = 9.82 min (linear gradient system of 30−100% B in A for
20 min). HRMS(ESI) m/z calcd for C19H12Cl2N4O5S2 [M+H]
+,
510.96261; found 510.97205.
(Z)-32a. Brown ﬂuﬀy solid; yield 0.02 g (8%); mp 200−202 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 4.19 (s, 2H), 4.29 (d, 1H, J =
15.0 Hz), 4.73 (d, 1H, J = 20.0 Hz), 7.52−7.57 (m, 2H), 7.69−7.72
(m, 1H), 8.00 (s, 1H), 8.05 (d, 1H, 5.0 Hz), 8.13 (s, 1H), 12.71 (s,
1H). 13C NMR (DMSO-d6, 125 MHz) in ppm: δ 36.8, 45.1, 115.8,
125.2, 126.7, 128.9, 129.1, 131.1, 131.7, 132.3, 134.1, 149.8, 164.6,
167.4. Purity of 95.1% as determined by RP-HPLC, tR = 10.38 min
(linear gradient system of 30−100% B in A for 20 min). HRMS(ESI)
m/z calcd for C19H12Cl2N4O5S2 [M+H]
+, 510.96261; found
510.97105.
Synthesis of (E/Z)-2-(2-(7,8-Dichloro-4H-5-oxothiochromeno[4,3-
d]thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
32b]. Step A. Synthesis of 31b followed the identical procedure as
described for 31a.
31b. Yield 0.186 g (50%). ESI-MS calcd MW for C10H7Cl2N3OS2,
320.22; found, m/z = 319.77 (M − H)−.
Step B. Synthesis of (E)-32b and (Z)-32b followed the identical
procedure as described for (E)-29a and (Z)-29a adjusted to 0.58
mmol scale for the 31b and 2-(o-nitrophenyl)pyruvic acid.
(E)-32b. Brown ﬂuﬀy solid; yield 0.056 g (18%); mp 190−192 °C
(dec). 1H NMR (DMSO-d6, 500 MHz) in ppm: δ 4.27−4.31 (m, 3H),
4.95−5.01 (m, 1H), 7.06−7.07 (m, 1H), 7.48−7.51 (m, 1H), 7.62−
7.65 (m, 1H), 7.86−7.94 (m, 1H), 8.05−8.08 (m, 1H), 12.24 (s, 1H).
13C NMR (DMSO-d6, 125 MHz) in ppm: δ 30.0, 40.4, 125.5, 125.7,
128.5, 129.5, 131.6, 133.4, 134.6, 134.9, 136.6, 149.6, 165.9. Purity of
98.2% as determined by RP-HPLC, tR = 8.74 min (linear gradient
system of 30−100% B in A for 26 min). HRMS(ESI) m/z calcd for
C19H12Cl2N4O5S2 [M+H]
+, 510.96261; found 510.96985.
(Z)-32b. Brown ﬂuﬀy solid; yield 0.015 g (5%); mp > 300 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 4.17−4.29 (m, 3H), 4.90 (d,
1H, J = 17.6 Hz), 7.51−7.59 (m, 2H), 7.68−7.73 (m, 1H), 7.89−7.96
(m, 2H), 8.04 (d, 1H, J = 8 Hz), 13.03 (s, 1H). 13C NMR (DMSO-d6,
100 MHz) in ppm: δ 45.0, 125.2, 125.8, 128.9, 129.9, 131.6, 132.6,
133.3, 133.6, 134.2, 134.8, 136.6, 149.8. Purity of 96.0% as determined
by RP-HPLC, tR = 10.12 min (linear gradient system of 30−100% B in
A for 26 min). HRMS(ESI) m/z calcd for C19H12Cl2N4O5S2 [M+H]
+,
510.96261; found 510.96978.
Synthesis of 1,1-Dioxo-3-bromo-6,7-dichloro-2,3-dihydrothio-
chromen-4-one (33a). A solution of m-chloroperbenzoic acid (2.21
g, 12.8 mmol) in chloroform (10 mL) was added dropwise over 30
min to a stirred solution of 27a (1.0 g, 3.20 mmol) in chloroform (40
mL) at 60 °C. The resultant mixture was reﬂuxed for 6 h and cooled to
RT. The precipitated sulfone was ﬁltered and dried. Additional
product was obtained by consecutive washings of the ﬁltrate with
saturated NaHCO3 solution (100 mL) and water (100 mL). The
separated organic phase was dried over anhydrous Na2SO4, ﬁltered,
and evaporated under vacuum and combined with the previously
obtained precipitate to aﬀord the sulfone 33a.
33a. Oﬀ-white solid; yield 0.8 g (72%); mp 255−256 °C. 1H NMR
(DMSO-d6, 500 MHz) in ppm: δ 4.65−4.68 (m, 1H), 4.77−4.82 (m,
1H), 5.87−5.91 (m, 1H), 8.22 (d, 1H), 8.28 (d, 1H). 13C NMR
(DMSO-d6, 125 MHz) in ppm: δ 46.4, 56.6, 126.2, 128.4, 131.37,
137.7, 139.2, 141.5, 184.2. Purity of 100% as determined by RP-HPLC,
tR = 8.79 min (linear gradient system of 30−100% B in A for 20 min).
ESI-MS calcd MW for C9H5BrCl2O3S, 344.01; found, m/z = 342.76 (M
− H)−.
Synthesis of 1,1-Dioxo-3-bromo-7,8-dichloro-2,3-dihydrothio-
chromen-4-one (33b). A solution of m-chloroperbenzoic acid (1.21
g, 6.9 mmol) in chloroform (15 mL) was added dropwise over 30 min
to a solution of 27b (0.543 g 1.74 mmol) in chloroform (10 mL) that
was kept at 60 °C. After reﬂuxing the reaction mixture for 12 h, it was
cooled to RT, diluted with dichloromethane (50 mL), and washed
with saturated NaHCO3 solution (3 × 100 mL) and water (100 mL).
The organic phase was dried over anhydrous Na2SO4, ﬁltered, and
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evaporated under vacuum to yield an oily residue, which yielded 33b
following trituration with ice-cold hexane.
33b. White solid; yield 0.5 g (83%); mp 254−255 °C (dec.). Purity
of 98.1% as determined by RP-HPLC, tR = 14.55 min (linear gradient
system of 0−100% B in A for 26 min). ESI-MS calcd MW for
C9H5BrCl2O3S, 344.01; found, m/z = 342.82 [M − H]−.
Synthesis of (E/Z)-2-(2-(7,8-Dichloro-4H-thiodioxochromeno[4,3-
d]thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
35a]. Step A. A solution of 33a (0.7 g, 2 mmol) and thiosemicarbazide
(0.181 g, 2 mmol) in anhydrous dioxane (30 mL) was stirred at 90 °C
for 2 d. Cooling the reaction mixture to RT resulted in a precipitate
that was ﬁltered, washed with dioxane (10 mL), and dried. The solid
was triturated in 2 M Na2CO3 (40 mL), ﬁltered, washed thoroughly
with water, and dried to yield the respective crude 34a.
34a. Yield 0.230 g (33%). ESI-MS calcd MW for C10H7Cl2N3O2S2,
336.22; found, m/z = 337.84 (M + H)+.
Step B. The 2-(o-nitrophenyl)pyruvic acid (0.154 g, 0.74 mmol)
was added to a suspension of 34a (0.25 g, 0.74 mmol) in acetic acid
(20 mL), and the reaction mixture was stirred at RT for 4 h. The
formed precipitate was ﬁltered, washed thoroughly with glacial acetic
acid (20 mL), and dried to give (E)-35a. Diluting the combined acetic
acid ﬁltrates with water (100 mL) generated a precipitate that was
washed with methanol to aﬀord (Z)-35a.
(E)-35a. Brown ﬂuﬀy solid; yield 0.16 g, (41%). mp 240−241 °C.
1H NMR (DMSO-d6, 400 MHz) in ppm: δ 4.28 (s, 2H), 5.11 (s, 2H),
7.06 (d, 1H, J = 8 Hz), 7.48−7.52 (m, 1H), 7.61−7.65 (m, 1H), 7.91
(s, 1H), 8.02−8.07 (m, 2H), 12.32 (bs, 1H). 13C NMR (DMSO-d6,
100 MHz) in ppm: δ 30.1, 49.2, 125.7, 125.8, 126.0, 127.5, 128.5,
129.6, 131.4, 131.5, 131.6, 134.6, 135.3, 137.4, 149.6, 165.8. Purity of
98.7% as determined by RP-HPLC, tR = 12.41 min (linear gradient
system of 30−100% B in A for 26 min). HRMS(ESI) m/z calcd for
C19H12Cl2N4O6S2 [M+H]
+, 526.95753; found 526.96875.
(Z)-35a. Gray ﬂuﬀy solid; yield 0.065 g, (17%). mp 248−249 °C.
1H NMR (DMSO-d6, 400 MHz) in ppm: δ 4.18 (s, 2H), 5.04 (s, 2H),
7.51−7.71 (m, 3H), 8.02−8.05 (m, 3H), 12.74 (s, 1H). 13C NMR
(DMSO-d6, 100 MHz) in ppm: δ 36.9, 49.17, 117.5, 125.2, 125.8,
129.0, 131.2, 131.7, 132.2, 133.6, 134.2, 135.2, 136.2, 137.5, 140.7,
149.6, 164.7, 167.5. Purity of 99.2% as determined by RP-HPLC, tR =
13.63 min (linear gradient system of 30−100% B in A for 26 min).
HRMS(ESI) m/z calcd for C19H12Cl2N4O6S2 [M+H]
+, 526.95753;
found 526.96705.
Synthesis of (E/Z)-2-(2-(7,8-Dichloro-4H-thiodioxochromeno[4,3-
d]thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
35b]. Step A: Synthesis of 7,8-Dichloro-2-hydrazinyl-4H-
thiochromeno[4,3-d]thiazole 5,5-Dioxide (34b). Synthesis of 34b
followed the identical procedure as described for 34a.
34b. Yield 0.350 g (50%). ESI-MS calcd MW for C10H7Cl2N3O2S2,
336.22; found, m/z = 337.97 (M + H)+.
Step B. To a suspension of 34b (0.25 g, 0.74 mmol) in acetic acid
(20 mL) was added 2-(o-nitrophenyl)pyruvic acid (0.155 g, 0.74
mmol). The reaction mixture was stirred at RT for 4 h and then
diluted with water (100 mL). The precipitated solid was ﬁltered and
dried. The crude mixture was puriﬁed on a RP-C18 FCC (100 g
cartridge, ﬂow rate = 40 mL/min) using a solvent system consisting of
A, triethylammonium bicarbonate buﬀer (50 mM, pH = 8.5), and B,
methanol. The puriﬁed isomers (E)-35b and (Z)-35b were
precipitated from their respective pooled fractions following addition
of 10% HCl (pH = 2) and separated by centrifugation. The pellets
were washed consecutively with 5% (v/v) HCl and water and dried
under vacuum to yield the following:
(E)-35b. Oﬀ-white ﬂuﬀy solid; yield 0.080 g (20%); mp 236−237
°C. 1H NMR (DMSO-d6, 500 MHz) in ppm: δ 4.29 (s, 2H), 5.19 (s,
2H), 7.07 (d, 1H, J = 5 Hz), 7.49−7.51 (m, 1H), 7.62−7.65 (m, 1H),
7.84−7.87 (m, 1H), 7.94−7.98 (m, 1H), 8.05−8.07 (m, 1H), 12.20 (s,
1H). 13C NMR (DMSO-d6, 125 MHz) in ppm: δ 30.1, 51.1, 125.7,
126.5, 128.5, 128.7, 129.6, 131.5, 133.4, 134.4, 134.5, 135.2, 149.6,
165.8. Purity of 99.9% as determined by RP-HPLC, tR = 11.48 min
(linear gradient system of 30−100% B in A for 26 min). HRMS(ESI)
m/z calcd for C19H12Cl2N4O6S2 [M + H]
+, 526.95753; found
526.95913.
(Z)-35b. Pale-green ﬂuﬀy solid; yield 0.045 g (11%); mp 247−248
°C. 1H NMR (DMSO-d6, 400 MHz) in ppm: δ 4.18 (s, 2H), 5.13 (s,
2H), 7.51−7.57 (m, 2H), 7.70 (t, 1H, J = 8 Hz), 7.90−7.95 (m, 2H),
8.04 (d, 1H, J = 8 Hz), 12.70 (s, 1H). 13C NMR (DMSO-d6, 100
MHz) in ppm: δ 36.9, 51.0, 115.9, 125.2, 126.9, 128.5, 129.0, 132.1,
132.3, 133.5, 133.6, 134.2, 134.3, 135.8, 136.1, 141.4, 149.6, 164.7,
167.3. Purity of 99.9% as determined by RP-HPLC, tR = 12.41 min
(linear gradient system of 30−100% B in A for 26 min). HRMS(ESI)
m/z calcd for C19H12Cl2N4O6S2 [M + H]
+, 526.95753; found
526.96467.
Synthesis of 3-Chloro-1-(2-hydroxy-4,5-dimethoxyphenyl)-
propan-1-one (37). The borontriﬂuoride etherate (1.25 mL, 10
mmol) was added dropwise over 3 min to a mixture of 3,4-
dimethoxyphenol (1.5 g, 10 mmol) and 2-chloropropanoyl chloride
(1.8 mL, 20 mmol) and kept at 60 °C for 3 h. The reaction was
quenched by pouring the mixture into a mixture of ice-cold water (30
mL) and dichloromethane (30 mL) and stirred overnight at RT. The
organic phase was separated, dried with anhydrous Na2SO4, and
concentrated under vacuum. The crude product was subjected to silica
gel FCC employing hexane−ethyl acetate mixture (9:1, v/v) as eluent
followed by recrystallization from dichloromethane to obtain 37.
37. Yellow crystals; Rf 0.85 (dichloromethane, silica gel); yield 1.0 g
(44%); mp 133−135 °C. 1H NMR (CDCl3, 500 MHz) in ppm: δ 3.36
(t, 2H), 3.83 (s, 3H), 3.88 (s, 3H), 3.87−3.90 (m, 2H), 6.42 (s, 1H),
6.98 (s, 1H). 13C NMR (CDCl3, 125 MHz) in ppm: δ 38.7, 40.7, 56.4,
56.8, 100.8, 110.6, 111.3, 142.3, 157.3, 160.5, 200.1. Purity of 96.7% as
determined by RP-HPLC, tR = 13.98 min (linear gradient system of
0−100% B in A for 26 min).
Synthesis of 6,7-Dimethoxy-2,3-dihydrochromene-4-one (43a). A
mixture of 37 (0.2 g, 0.8 mmol) and K2CO3 (0.56 g, 40 mmol) in
ethanol (10 mL) was stirred for 20 h at RT. The reaction mixture was
ﬁltered, and the ﬁltrate was concentrated under vacuum to aﬀord a
yellow residue. The residue was diluted with ethyl acetate (20 mL) and
water (20 mL). The organic phase was washed with 5% (w/v)
NaHCO3 solution (20 mL), dried over anhydrous Na2SO4, and
concentrated under vacuum. The resultant residue was puriﬁed on a
silica gel FCC using cyclohexane−ethyl acetate mixture (7:3, v/v) as
eluent to yield.
43a. Oﬀ-white solid; Rf 0.35 (cyclohexane−ethyl acetate, 7:3 (v/v),
silica gel); yield 0.07 g (42%); mp 124−127 °C. 1H NMR (CDCl3,
400 MHz) in ppm: δ 2.70−2.73 (m, 2H), 3.82 (s, 3H), 3.88 (s, 3H),
4.45−4.49 (m, 2H), 6.39 (s, 1H), 7.26 (s, 1H). 13C NMR (CDCl3, 100
MHz) in ppm: δ 37.4, 56.3, 56.4, 67.7, 100.2, 106.9, 113.7, 114.6,
156.2, 158.5, 190.7. Purity of 98.9% as determined by RP-HPLC, tR =
9.75 min (linear gradient system of 0−100% B in A for 26 min). ESI-
MS calcd MW for C11H12O4, 208.21; found, m/z = 206.73 (M − H)−.
Synthesis of 3-Bromo-6,7-dimethoxy-2,3-dihydrochromen-4-one
(44a). Synthesis of 44a followed the identical procedure as described
for 21a adjusted to 2.8 mmol scale for the 43a and pyridinium
bromide perbromide.
44a. Oﬀ-white solid; Rf 0.41 (cyclohexane−ethyl acetate, 7:3 (v/v),
silica gel); yield 0.6 g (75%); mp 154−156 °C. 1H NMR (CDCl3, 400
MHz) in ppm: δ 3.89 (s, 3H), 3.90 (s, 3H), 4.53−4.62 (m, 3H), 6.46
(s, 1H), 7.27 (s, 1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 45.4,
56.4, 56.6, 72.1, 100.1, 107.5, 111.1, 145.5, 157.1, 157.5, 184.1. Purity
of 97.1% as determined by RP-HPLC, tR = 5.77 min (linear gradient
system of 30−100% B in A for 26 min). ESI-MS calcd MW for
C11H11BrO4, 287.11; found, m/z = 288.95 [M + H]
+.
Synthesis of (E/Z)-2-(2-(7,8-Dimethoxy-4H-chromeno[4,3-d]-
thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
46a]. Step A: Synthesis of 1-(7,8-Dimethoxy-4H-chromeno[4,3-
d]thiazol-2-yl)hydrazine (45a). A solution of 3-bromo-6,7-dimethoxy-
2,3-dihydrochromen-4-one (0.5 g, 1.7 mmol) and thiosemicarbazide
(0.157 g, 1.7 mmol) in anhydrous dioxane (20 mL) was stirred at 80
°C for 2 d. The resulting yellow precipitate was ﬁltered, washed with
dioxane (10 mL), triturated in 2 M Na2CO3 solution (30 mL), and
ﬁltered, and washed thoroughly with water and dried to aﬀord the
crude 45a.
45a. Oﬀ-white solid; yield 0.34 g (72%). ESI-MS calcd MW for
C12H13N3O3S, 279.31; found, m/z = 279.73 (M − H)−.
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Step B. Synthesis of (E)-46a, and (Z)-46a followed the identical
procedure as described for (E)-13a and (Z)-13a adjusted to 0.7 mmol
scale for the 45a and 2-(o-nitrophenyl)pyruvic acid.
(E)-46a. Yellow powder; yield 0.055 g (17%); mp 202−204 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 3.67 (s, 3H), 3.73 (s, 3H),
4.29 (s, 2H), 5.29 (s, 2H), 6.61 (s, 1H), 6.98 (s, 1H), 7.08 (d, 1H, J =
7.5 Hz), 7.49−7.52 (m, 1H), 7.63−7.66 (m, 1H), 8.06 (d, 1H, J = 8.5
Hz), 12.58 (s, 2H). 13C NMR (DMSO-d6, 125 MHz) in ppm: δ 29.8,
56.3, 56.4, 64.7, 102.2, 106.1, 125.7, 128.5, 129.5, 131.7, 134.5, 144.3,
147.9, 149.7, 149.8, 166.1. Purity of 99.0% as determined by RP-
HPLC, tR = 9.07 min (linear gradient system of 30−100% B in A for
26 min). HRMS(ESI) m/z calcd for C21H18N4O7S [M + H]
+,
471.08961; found 471.09633.
(Z)-46a. Yellow powder; yield 0.06 g (18%); mp 238−240 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 3.67 (s, 6H), 4.16 (s, 2H),
5.20 (s, 2H), 6.57 (s, 1H), 7.02 (s, 1H), 7.50−7.55 (m, 2H), 7.67−
7.69 (m, 1H), 8.03−8.05 (m, 1H), 12.78 (s, 1H). 13C NMR (DMSO-
d6, 125 MHz) in ppm: δ 36.7, 56.3, 56.5, 64.6, 102.1, 106.4, 125.2,
128.9, 132.5, 133.6, 134.2, 144.3, 147.8, 149.7, 149.9, 164.7. Purity of
99.5% as determined by RP-HPLC, tR = 10.90 min (linear gradient
system of 30−100% B in A for 26 min). HRMS(ESI) m/z calcd for
C21H18N4O7S [M + H]
+, 471.08961; found 471.09668.
Synthesis of 3-(2,3-Dimethoxyphenoxy)propanoic Acid (42). The
oxetan-2-one (1.8 g, 2.5 mmol) was added dropwise during 5 min to a
stirred solution of 2,3-dimethoxyphenol (4.0 g, 25 mmol) in 0.625 M
NaOH (40 mL), and the mixture was kept at 100 °C for 3 h. After
cooling to RT, the reaction mixture was diluted with water (50 mL)
followed by acidiﬁcation with concd HCl (10 mL). The product was
extracted into diethyl ether (2 × 100 mL), and the combined ethereal
phases were then washed with 10% (w/v) NaHCO3 solution (100
mL). The separated aqueous phase was acidiﬁed with concd HCl to
pH = 2 and kept at 4 °C overnight to aﬀord 42.
42. Oﬀ-white solid; yield 2.5 g (40%); mp 104−106 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.89 (t, 2H, J = 6.4 Hz), 3.81 (s, 3H),
3.85 (s, 3H), 4.29 (t, 2H, J = 6.4 Hz), 6.59 (d, 2H, J = 8.8 Hz), 6.94−
6.97 (m, 1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 34.6, 56.3,
61.0, 64.6, 106.1, 107.4, 123.8, 138.9, 152.4, 153.8, 177.0. Purity of
93.5% as determined by RP-HPLC, tR = 9.81 min (linear gradient
system of 0−100% B in A for 26 min). ESI-MS calcd MW for
C11H14O5, 226.23; found, m/z = 224.99 (M − H)−.
Synthesis of 7,8-Dimethoxy-2,3-dihydrochromen-4-one (43b).
To a solution of 42 (1.1 g, 4.8 mmol) dissolved in dry benzene (40
mL) was added phosphorus pentoxide (6 g) and reﬂuxed for 4 h and
then cooled to RT. Benzene was decanted oﬀ, and the residue was
triturated with benzene (2 × 10 mL) and collected with the previously
decanted solvent. Ice-cold water (20 mL) was added dropwise to the
residual slurry of phosphorus pentoxide, and the mixture was extracted
with benzene (20 mL). The combined benzene fractions were washed
successively with 10% (v/v) NaHCO3 (40 mL), 1N NaOH (40 mL),
and water (40 mL). The organic phase was dried over anhydrous
Na2SO4, ﬁltered, and evaporated under vacuum to yield 43b.
43b. Pale-yellow solid; yield 0.8 g (79%); mp 102−104 °C. 1H
NMR (CDCl3, 400 MHz) in ppm: δ 2.72−2.75 (m, 2H), 3.83 (s, 3H),
3.89 (s, 3H), 4.53−4.56 (m, 2H), 6.60 (d, 1H, J = 8.0 Hz), 7.64 (d,
1H, J = 8.0 Hz). 13C NMR (CDCl3, 100 MHz) in ppm: δ 37.7, 56.3,
61.2, 67.8, 105.7, 116.7, 123.3, 136.9, 155.9, 158.7, 190.8. Purity of
95.81% as determined by RP-HPLC, tR = 9.44 min (linear gradient
system of 0−100% B in A for 26 min). ESI-MS calcd MW for
C11H12O4, 208.21; found, m/z = 208.91 (M + H)
+.
Synthesis of 3-Bromo-7,8-dimethoxy-2,3-dihydrochromen-4-one
(44b). Synthesis of 44b followed the identical procedure as described
for 21a adjusted to 2.4 mmol scale for ketone 43b and pyridinium
bromide perbromide.
44b. Pale-yellow solid; yield 0.33 g (48%); mp 118−120 °C. 1H
NMR (CDCl3, 400 MHz) in ppm: δ 3.86 (s, 3H), 3.92 (s, 3H), 4.57−
4.60 (m, 1H), 4.63−4.68 (m, 2H), 6.69 (d, 1H, J = 8.0 Hz), 7.69 (d,
1H, J = 8.0 Hz). 13C NMR (CDCl3, 100 MHz) in ppm: δ 45.4, 56.5,
61.4, 71.9, 106.8, 113.9, 124.5, 136.8, 154.8, 159.4, 184.4. Purity of
97.3% as determined by RP-HPLC, tR = 5.84 min (linear gradient
system of 30−100% B in A for 26 min). ESI-MS calcd MW for
C11H11BrO4, 287.11; found, m/z = 286.84 [M + H]
+.
Synthesis of (E/Z)-2-(2-(6,7-Dimethoxy-4H-chromeno[4,3-d]-
thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
46b]. Step A: Synthesis of 1-(6,7-Dimethoxy-4H-chromeno[4,3-
d]thiazol-2-yl)hydrazine, (45b). A solution of 44b (0.4 g, 1.36 mmol)
and thiosemicarbazide (0.158 g, 1.36 mmol) in anhydrous dioxane (20
mL) was stirred at 50 °C for 24 h, and the resulting precipitate was
ﬁltered, washed with dioxane (10 mL), and triturated with 2 M
Na2CO3 (15 mL) to aﬀord the crude 45b, which was used as such in
the next step.
45b. White powder; yield 0.18 g (38%). ESI-MS calcd MW for
C12H13N3O3S, 279.31; found, m/z = 279.90 (M + H)
+.
Step B. Synthesis of (E)-46b and (Z)-46b followed the identical
procedure as described for (E)-13a and (Z)-13a adjusted to 0.5 mmol
scale for the 45b and 2-(o-nitrophenyl)pyruvic acid.
(E)-46b. Yellow solid; yield 0.08 g (34%); mp 258−260 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 3.67 (s, 3H), 3.74 (s, 3H),
4.27 (s, 2H), 5.34 (s, 2H), 6.62 (d, 1H, J = 8 Hz), 7.06 (d, 1H, J = 8
Hz), 7.12 (d, 1H, J = 8 Hz), 7.49−7.51 (m, 1H), 7.63−7.65 (m, 1H),
8.05 (d, 1H, J = 8 Hz), 12.70 (s, 1H). 13C NMR (DMSO-d6, 100
MHz) in ppm: δ 29.8, 56.4, 60.9, 64.9, 125.6, 128.4, 131.7, 134.5,
137.9, 147.1, 148.5, 149.6, 166.1. Purity of 100% as determined by RP-
HPLC, tR = 8.78 min (linear gradient system of 30−100% B in A for
26 min). HRMS(ESI) m/z calcd for C21H18N4O7S [M + H]
+,
471.08961; found 471.09530.
(Z)-46b. Yellow solid; yield 0.03 g (13%); mp 239−241 °C. 1H
NMR (DMSO-d6, 400 MHz) in ppm: δ 3.66 (s, 3H), 3.75 (s, 3H),
4.16 (s, 2H), 5.27 (s, 2H), 6.63 (d, 1H, J = 8.8 Hz), 7.16 (d, 1H, J =
8.8 Hz), 7.50−7.56 (m, 2H), 7.67−7.71 (m, 1H), 8.03−8.05 (m, 1H),
12.78 (bs, 1H). 13C NMR (DMSO-d6, 100 MHz) in ppm: δ 36.8, 56.4,
60.9, 64.8, 106.0, 117.6, 125.2, 128.9, 132.5, 133.6, 134.2, 137.8, 147.0,
149.6, 153.8, 164.7. Purity of 97.9% as determined by RP-HPLC, tR =
10.38 min (linear gradient system of 30−100% B in A for 26 min).
HRMS(ESI) m/z calcd for C21H18N4O7S [M + H]
+, 471.08961; found
471.09987.
Synthesis of 4-(3,4-Dimethoxyphenyl)-4-oxobutanoic Acid (39).
Veratrole, 38 (7.0 g, 50 mmol), was added dropwise over 30 min to a
stirred suspension of succinic anhydride (6.0 g, 60 mmol) and AlCl3
(16.0 g, 120 mmol) in nitrobenzene (40 mL) that was maintained at
10 °C. The temperature was then slowly raised to RT, and the stirring
continued for 12 h. The reaction mixture was then poured into ice-
cold water and acidiﬁed with concd HCl to pH = 2. The formed
precipitate was ﬁltered oﬀ, redissolved in 1N NaOH (50 mL), and
extracted with ether (100 mL). The precipitate formed upon the
acidiﬁcation of the aqueous phase to pH = 2 with concd HCl was
ﬁltered, washed with water, and dried to yield 39.
39. Pale-yellow solid; yield 5.4 g (46%); mp 169−171 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.52−2.55 (m, 2H), 3.17−3.20 (m,
2H), 3.79 (s, 3H), 3.82 (s, 3H), 7.04 (d, J = 8.0 Hz, 1H), 7.43 (d, J =
4.0 Hz, 1H), 7.62−7.64 (m, 1H). 13C NMR (CDCl3, 100 MHz) in
ppm: δ 28.6, 33.3, 56.1, 56.3, 110.7, 11.5, 123.1, 130.0, 149.1, 153.6,
174.5, 197.4. Purity of 92.7% as determined by RP-HPLC, tR = 9.22
min (linear gradient system of 0−100% B in A for 26 min). ESI-MS
calcd MW for C12H14O5, 238.24; found, m/z = 238.80 (M + H)
+.
Synthesis of 6,7-Dimethoxy-3,4-dihydronaphthalen-1(2H)-one
(43c). Step 1. Synthesis of 40 followed the identical procedure as
described for 8a adjusted to 18 mmol scale for 39 and used in the next
step without puriﬁcation.
40. Brownish oil; yield 3.0 g (70%). Purity of 60.5% as determined
by RP-HPLC, tR = 10.64 min (linear gradient system of 0−100% B in
A for 26 min). ESI-MS calcd MW for C12H16O4, 224.25; found, m/z =
224.93 (M + H)+.
Step 2. 40 (3.0 g, 13.3 mmol) was added to a melt of
polyphosphoric acid (50 g) and stirred for 6 h at 90 °C. The reaction
mixture was cooled to RT and diluted with ice-cold water (100 mL). It
was extracted with ethyl acetate (100 mL), washed with a saturated
solution of NaHCO3 (100 mL), dried over anhydrous Na2SO4, and
evaporated under vacuum. The oily residue was crystallized from
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hexane−ethyl acetate (1:1) followed by trituration with diethyl ether
to aﬀord 43c.
43c. Colorless solid; yield 2.0 g (57%); mp 98−100 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.03−2.08 (m, 2H), 2.50−2.54 (m,
2H), 2.81−2.84 (m, 2H), 3.84 (s, 3H), 3.87 (s, 3H), 6.61 (s, 1H), 7.45
(s, 1H). 13C NMR (CDCl3, 100 MHz) in ppm: δ 23.8, 29.6, 30.7, 56.1,
56.2, 108.6, 110.3, 125.9, 139.5, 148.0, 153.6, 197.3. Purity of 98.99%
as determined by RP-HPLC, tR = 10.82 min (linear gradient system of
0−100% B in A for 26 min). ESI-MS calcd MW for C12H14O3, 206.24;
found, m/z = 207.97 (M + H)+.
Synthesis of 2-Bromo-6,7-dimethoxy-3,4-dihydronaphthalen-
1(2H)-one (44c). Synthesis of 44c followed the identical procedure
as described for 21a adjusted to 2.4 mmol scale for the 43c, and the
crude was puriﬁed by silica gel FCC using a mixture of hexane−ethyl
acetate (8:2, v/v).
44c. Oﬀ-white solid; yield 0.5 g (74%); mp 110−112 °C. 1H NMR
(CDCl3, 400 MHz) in ppm: δ 2.39−2.49 (m, 2H), 2.75−2.81 (m,
1H), 3.18−3.24 (m, 1H), 3.86 (s, 3H), 3.90 (s, 3H), 4.64−4.65 (m,
1H), 6.64 (s, 1H), 7.47 (s, 1H). 13C NMR (CDCl3, 100 MHz) in
ppm: δ 26.0, 32.4, 56.2, 56.3, 109.7, 110.2, 123.1, 138.3, 148.5, 154.4,
189.7. Purity of 97.0% as determined by RP-HPLC, tR = 13.24 min
(linear gradient system of 0−100% B in A for 26 min). ESI-MS calcd
MW for C12H13BrO3, 285.13; found, m/z = 287.97 (M + H)
+.
Synthesis of (E/Z)-2-(2-(7,8-Dimethoxy-4,5-dihydronaphtho[1,2-
d]thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic Acid [(E/Z)-
46c]. Step A: Synthesis of 1-(7,8-Dimethoxy-4,5-dihydronaphtho-
[1,2-d]thiazol-2-yl)hydrazine (45c). A solution of 44c (0.4 g, 1.4
mmol) and thiosemicarbazide (0.127 g, 1.4 mmol) in anhydrous
dioxane (20 mL) was stirred at 80 °C for 2 d. Cooling to RT aﬀorded
a yellow precipitate that was ﬁltered, washed with dioxane (10 mL),
and dried. The solid was triturated with a 2 M Na2CO3 (40 mL),
ﬁltered, washed thoroughly with water, and dried to yield crude 45c.
45c: Oﬀ-white powder, yield 0.25 g (64%). ESI-MS calcd MW for
C13H15N3O2S, 277.34; found, m/z = 278.01 (M + H)
+.
Step B. Synthesis of (E)-46c and (Z)-46c followed the identical
procedure as described for (E)-13a and (Z)-13a adjusted to 0.5 mmol
scale for the 45c and 2-(o-nitrophenyl)pyruvic acid.
(E)-46c. Yellow powder; yield 0.058 g (25%); mp 183−184 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 2.77−2.80 (m, 2H), 2.86−
2.89 (m, 2H), 3.67 (s, 3H), 3.70 (s, 3H), 4.27 (s, 2H), 6.86 (s, 1H),
7.05 (d, 1H, J = 8.0 Hz), 7.13 (s, 1H), 7.47−7.50 (m, 1H), 7.61−7.65
(m, 1H), 8.04 (d, 1H, J = 8.5 Hz). 13C NMR (DMSO-d6, 125 MHz) in
ppm: δ 21.9, 28.4, 29.7, 56.0, 56.2, 106.7, 113.0, 125.6, 127.4, 128.4,
129.6, 131.9, 134.4, 148.0, 148.2, 149.7, 166.2. Purity of 97.6% as
determined by RP-HPLC, tR = 10.00 min (linear gradient system of
30−100% B in A for 26 min). HRMS(ESI) m/z calcd for
C22H20N4O6S [M + H]
+, 469.11035; found 469.11588.
(Z)-46c. Yellow powder; yield 0.037 g (16%); mp 259−260 °C. 1H
NMR (DMSO-d6, 500 MHz) in ppm: δ 2.72−2.74 (m, 2H), 2.82−
2.85 (m, 2H), 3.73 (s, 6H), 4.16 (s, 2H), 6.84 (s, 1H), 7.15 (s, 1H),
7.49−7.56 (m, 2H), 7.67−7.71 (m, 1H), 8.03−8.05 (m, 1H). 13C
NMR (DMSO-d6, 125 MHz) in ppm: δ 21.8, 28.3, 36.6, 56.2, 125.2,
127.4, 128.8, 132.7, 133.5, 134.1, 148.0, 148.4, 149.7, 164.6. Purity of
99.3% as determined by RP-HPLC, tR = 11.22 min (linear gradient
system of 30−100% B in A for 26 min). HRMS(ESI) m/z calcd for
C22H20N4O6S [M + H]
+, 469.11035; found 469.11944.
Biology. Fluorescent Polarization Assay. The C-terminal
ﬂuorescein-labeled peptide KKQYDREFLLDFQFK was synthesized
by Research Genetics. This sequence contains the Y(X)4LΦ motif and
was optimized for solubility and binding to eIF4E. A truncated eIF4E
containing a deletion of N-terminal 26 amino acids was expressed as a
GST fusion protein (GST-DN26-eIF4E). For the screening assay, a
solution containing approximately 0.5 mM GST-DN26-eIF4E, 20 nM
labeled peptide, and 2 mM DTT in a buﬀer composed of 50 mM
sodium phosphate and 50 mM potassium chloride at pH 6.5 was used.
Measurements of FP and ﬂuorescent anisotrophy (FA) were made in
black 384-well plates (Corning) using a Perkin Elmer Wallac EnVision
2100 Multilabel Reader.
Antiproliferation Activity. The antiproliferation activity of rigidiﬁed
mimetic of 1 were investigated on CRL-2813 cell lines and CRL-2351
cell lines by sulforhodamine B (SRB) assay. Adherent human breast
cancer and melanoma cells (CRL-2351 and CRL-2813) were plated in
96-well plates and maintained for 5 days in the presence of 0.54−20
μM compounds, and cell proliferation was measured by the SRB assay.
Brieﬂy, cells were ﬁxed in 10% cold trichloroacetic acid at 4 °C
overnight, extensively washed with double-distilled H2O, and air-dried.
Plates were then incubated with 0.057% SRB in 1% acetic acid for 1 h
at RT, washed with 1% acetic acid to remove the unbound dye, and
air-dried. The bound dye was solubilized by addition of 10 mM Tris
(pH 10), and the absorbance was determined in a Thermo Scientiﬁc
Multiskan FC plate reader at 510 nm. The data calculations were
carried out as described.63
Assessment of the Disruption of eIF4E/eIF4G Interaction by the
m7GTP Pull-Down Assay. Melanoma CRL-2813 cell lines were
incubated for 3 h in the presence of the 30 μM of each of the
compounds and 0.4% DMSO, harvested by centrifugation, and lysed
by multiple freeze−thaw cycles. Subsequently, the lysate was incubated
with m7GTP−Sepharose beads for 1 h at 4 °C to pull-down eIF4E.
The beads were separated, extensively washed, and the bound eIF4E
eluted with free m7GTP, the supernatant was separated by SDS-PAGE,
and Western blotted by polyclonal antibodies against 4E-BP1 and
monoclonal antibodies against eIF4E and eIF4G.
Western Blot Analysis. Western blot analysis was carried out as
described.64 Anti-eIF4E antibody (catalogue no. 610269) was from BD
Transduction Laboratories (San Jose, CA). anti-4EBP-1 (catalogue no.
9452S) and anti-eIF4G (catalogue no. 2498S) antibodies were
purchased from Cell Signaling Technology, Inc. (Danvers, MA).
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